




























































A THESIS SUBMITTED 
 
FOR THE DEGREE OF DOCTOR OF PHILOSOPHY 
 














This thesis is dedicated to my late parents who had taught me the real meaning of love, 
sacrifice, and self-giving through their lifetime. It was only through their hardships, 
sacrifices, and unwavering visions for the future of their children that I could have 
ample opportunities to experience what many others could only have longed for.  
  i 
ACKNOWLEDGEMENT 
 
First of all, I would like to express my deepest and most sincere gratitude to 
both my thesis advisors, Prof. Tong Yen Wah and Prof. Yang Yi-Yan, for their 
invaluable guidance, patience, and kind supervision. Being their PhD student has been 
one of the most fortunate moments in my life as it allowed me to experience extremely 
generous supports, as well as an unforgettable and precious friendship from them. In 
addition, I would also like to thank Prof. William B. Krantz, who has been an inspiring 
teacher for one of my coursework in 2006, as well as a dear friend and great mentor 
afterwards.  
The Chemical and Biomolecular Engineering Department (ChBE) of NUS and 
The Institute of Bioengineering and Nanotechnology (IBN) of A-star also deserve very 
special thanks for the financial supports and research facilities that make this study 
possible. I would like to also thank all the people whom I had worked with quite 
closely in the lab: Mr. Alvin Loo, Ms. Ashlynn Lee, Mr. Brian Liau, Mr. Cyrus Beh, 
Ms. Fanny Tandiono, Dr. Jeremy Tan, Dr. Majad Khan, Dr. Liu Lihong, Dr. Liu 
Shaoqiong, Dr. Peggy Chan, Mr. Phin Peng Lee, Mr. Seow Wei Yang, Mr. Tan Chuan 
Guan, Ms. Wang Li Shan, Dr. Wang Yong, Dr. Yang Chuan, Ms. Yong Lin Kin, Ms. 
Zhang Ying (from IBN), Mr. David Julius, Mr. Deny Hartono, Dr. Jeremy, Ms. 
Jessica, Dr. Khew Shih Tak, Mdm. Lee Feng Mei, Mdm. Li Xiang, Ms. Liang You 
Yun, Mr. Luo Jingnan, Dr. Natalia Widjojo, Ms. Niranjani, Dr. Tan Chau Jin, Mr. 
Usman Oemar, Dr. Zhu Xinhao (from ChBE), for their friendship and kind supports. 
All the undergraduate students who had worked with me in these institutes, Ms. Jenny 
Lee, Mr. Seow Kok Huei, Ms. Eng Shuen Huei, Mr. Kendrick Wong, Ms. Rachel 
Khor, Ms. Astrid Astarina and Ms. Juliana Au, also deserve big thanks for their 
  ii 
curiosities that stimulated ideas in my research works, as well as for their helping 
hands and youthfulness, which had added spirits and lives into my PhD studies. 
Last but not least, I would like to express my most sincere appreciation to my 
family members, especially my sister, for all her supports to me through all the 
problems that surfaced during this PhD study, as well as my late parents for their 
constant love through their lifetime, and encouragement when I began my PhD 
candidacy. My indebtedness also goes to all other friends that had supported me in 
many ways when I went through difficult phases in my personal life at the beginning 
of my postgraduate study.  
  iii 
TABLE OF CONTENTS 
 
ACKNOWLEDGEMENT..................................................................................................................I 
TABLE OF CONTENTS.................................................................................................................III 
SUMMARY ..................................................................................................................................... VI 
LIST OF TABLES........................................................................................................................ VIII 
LIST OF FIGURES......................................................................................................................... IX 
NOMENCLATURES .....................................................................................................................XII 
I. INTRODUCTION .................................................................................................................... 2 
1.1. BACKGROUND.................................................................................................................... 2 
1.2. OBJECTIVE AND SCOPE OF THE WORKS ............................................................................... 4 
1.2.1. Design and Synthesis of new biocompatible delivery vehicles for safe and efficient drug 
and/or gene therapy.................................................................................................................... 4 
1.2.2. Physicochemical characterization and the structure-activity relationship establishment of 
the amphiphilic peptide sequence to allow for simultaneous drug and gene delivery .................... 5 
1.2.3. Investigation on the co-delivery of anticancer drugs and genes for improved cancer therapy
................................................................................................................................................... 5 
1.2.4. Development of targeted cationic micelle system to achieve targeted co-delivery................ 5 
II. LITERATURE REVIEWS....................................................................................................... 8 
2.1. BRIEF DISCUSSION ON GENERAL HALLMARKS OF CANCERS................................................. 9 
2.2. OVERVIEW OF CANCER DRUG AND GENE DELIVERY BARRIERS ......................................... 12 
2.2.1. Overview on Challenges on Cancer Drug Therapy........................................................... 14 
2.2.2. Overview on Challenges in Cancer Gene Therapy. .......................................................... 16 
2.3. CURRENT TECHNOLOGIES FOR MICELLAR CANCER DRUG DELIVERY ................................. 18 
2.3.1. Introduction to Polymeric Micelles.............................................................................. 18 
2.3.2. Micellization. .............................................................................................................. 19 
2.3.3. Drug Solubilization into micellar core......................................................................... 22 
2.3.4. Micelle stability. ......................................................................................................... 24 
2.3.5. Functional micelles. .................................................................................................... 25 
2.4. CURRENT TECHNOLOGIES FOR NON-VIRAL CANCER GENE DELIVERY ................................ 29 
2.4.1. Classical Non-Viral Gene Delivery Vehicle. ................................................................ 31 
2.4.1.1. Cationic polymers................................................................................................... 31 
2.4.1.2. Cell Penetrating Peptides (CPP)............................................................................. 33 
2.4.1.3. Liposomes. ............................................................................................................. 34 
2.4.2. Poly Ionic Complex Micelle (PIC) for Non-Viral Gene Delivery Vehicle. ..................... 35 
2.4.3. Cationic Polymer Micelles for Gene Delivery Vehicle.................................................. 37 
2.4.4. Gene Delivery in Clinical Trials.................................................................................. 38 
2.4.5. Modification of Standard Non-Viral Gene Delivery Vehicle. ........................................ 39 
2.5. SUMMARY AND CONCLUDING REMARKS ........................................................................... 40 
III. DESIGN OF SELF-ASSEMBLED AMPHIPHILIC PEPTIDE FOR IN VITRO GENE 
CARRIER........................................................................................................................................ 43 
3.1. INTRODUCTION ................................................................................................................ 43 
3.2. MATERIALS AND METHODS .............................................................................................. 45 
3.2.1. Materials .................................................................................................................... 45 
3.2.2. Methods...................................................................................................................... 46 
3.2.2.1. CMC estimation ..................................................................................................... 46 
3.2.2.2. Preparation of peptide/DNA or PEI/DNA complexes............................................... 47 
3.2.2.3. Scanning Electron Microscopy (SEM) and Transmission Electron Microscopy (TEM)
 47 
3.2.2.4. DNA retardation assay ........................................................................................... 48 
3.2.2.5. Thiazole orange exclusion assay............................................................................. 48 
  iv 
3.2.2.6. DNA degradation assay.......................................................................................... 49 
3.2.2.7. Particle size and zeta potential measurements......................................................... 49 
3.2.2.8. Cell culture ............................................................................................................ 50 
3.2.2.9. Cytotoxicity test...................................................................................................... 50 
3.2.2.10. In vitro gene expression.......................................................................................... 51 
3.3. RESULTS AND DISCUSSIONS.............................................................................................. 52 
3.3.1. Micelle formation........................................................................................................ 52 
3.3.2. DNA binding ability of peptide .................................................................................... 54 
3.3.3. DNA degradation assay............................................................................................... 56 
3.3.4. Particle size, zeta potentials, and morphology analysis................................................ 58 
3.3.5. Cytotoxicity of peptide and peptide/DNA complex........................................................ 61 
3.3.6. Complexation pH-dependent in vitro gene expression.................................................. 62 
3.3.7. Luciferase expression in various cell lines ................................................................... 64 
3.4. CONCLUSIONS.................................................................................................................. 66 
IV. DESIGN AND EVALUATION OF PEPTIDE AMPHIPHILES WITH DIFFERENT 
HYDROPHOBIC BLOCKS FOR SIMULTANEOUS DELIVERY OF DRUGS AND GENES... 69 
4.1. INTRODUCTION ................................................................................................................ 69 
4.2. MATERIALS AND METHODS .............................................................................................. 72 
4.2.1. Materials .................................................................................................................... 72 
4.2.2. Methods...................................................................................................................... 73 
4.2.2.1. Peptide synthesis .................................................................................................... 73 
4.2.2.2. CMC determination................................................................................................ 74 
4.2.2.3. Particle size and zeta potential analysis .................................................................. 75 
4.2.2.4. Drug encapsulation ................................................................................................ 75 
4.2.2.5. In vitro drug release profile of doxorubicin............................................................. 77 
4.2.2.6. Cell culture ............................................................................................................ 77 
4.2.2.7. Cytotoxicity analysis............................................................................................... 78 
4.2.2.8. Luciferase gene expression ..................................................................................... 78 
4.2.2.9. Co-delivery of paclitaxel and luciferase gene .......................................................... 79 
4.3. RESULTS AND DISCUSSIONS.............................................................................................. 79 
4.3.1. Peptide synthesis and characterization ........................................................................ 79 
4.3.2. Effect of hydrophobic amino acid content on the CMC of nanostructures ..................... 80 
4.3.4. Encapsulation of DOX into core-shell peptide nanoparticles........................................ 84 
4.3.5. In vitro drug release profile......................................................................................... 86 
4.3.6. Effect of hydrophobicity on gene transfection and cytotoxicity. .................................... 87 
4.3.7. Co-delivery of PTX and Luciferase for synergistic effect. ............................................. 89 
4.4. CONCLUSIONS.................................................................................................................. 90 
V. SELF-ASSEMBLED OLIGOPEPTIDE NANOSTRUCTURES FOR SIMULTANEOUS 
DELIVERY OF DRUGS AND GENES WITH SYNERGISTIC EFFECT.................................... 92 
5.1. INTRODUCTION ................................................................................................................ 92 
5.2. MATERIALS AND METHODS .............................................................................................. 94 
5.2.1. Materials .................................................................................................................... 94 
5.2.2. Methods...................................................................................................................... 95 
5.2.2.1. Peptide synthesis .................................................................................................... 95 
5.2.2.2. Critical Micelle Concentration determination ......................................................... 96 
5.2.2.3. Loading of DOX into peptide micelles..................................................................... 96 
5.2.2.4. In vitro drug release of DOX................................................................................... 96 
5.2.2.5. Formation of peptide/DNA complexes..................................................................... 97 
5.2.2.6. Particle size and zeta potentials measurement......................................................... 97 
5.2.2.7. DNA retardation assay ........................................................................................... 97 
5.2.2.8. Cell culture ............................................................................................................ 98 
5.2.2.9. Cellular uptake of DOX .......................................................................................... 98 
5.2.2.10. Cytotoxicity of FA32, FA32/DNA complexes, DOX and DOX-loaded micelles ......... 99 
5.2.2.11. In vitro gene expression........................................................................................ 100 
5.2.2.12. Co-delivery of drugs and gene .............................................................................. 101 
5.3. RESULTS AND DISCUSSIONS............................................................................................ 103 
5.3.1. Peptide synthesis and Self-assembly .......................................................................... 103 
5.3.2. Particle size and Zeta potential analysis.................................................................... 103 
  v 
5.3.3. DOX loading and in vitro drug release ...................................................................... 105 
5.3.4. Cellular uptake of DOX............................................................................................. 106 
5.3.5. DNA retardation analysis.......................................................................................... 108 
5.3.6. Cytotoxicity of FA32, FA32/DNA complexes, free DOX and DOX-loaded micelles..... 109 
5.3.7. In vitro gene expression ............................................................................................ 111 
5.3.8. Simultaneous delivery of model drug and gene .......................................................... 112 
5.3.9. Co-delivery of DOX and Luciferase- or p53-encoding plasmid................................... 113 
5.4. CONCLUSIONS................................................................................................................ 117 
VI. GALACTOSE-COATED SELF-ASSEMBLED OLIGOPEPTIDE NANOSTRUCTURES 
VIA ELECTROSTATIC ADSORPTION FOR TARGETED SIMULTANEOUS DELIVERY OF 
ANTICANCER DRUGS AND GENES......................................................................................... 119 
6.1. INTRODUCTION .............................................................................................................. 119 
6.2. MATERIALS AND METHODS ............................................................................................ 121 
6.2.1. Materials .................................................................................................................. 121 
6.2.2. Methods.................................................................................................................... 123 
6.2.2.1. Peptide synthesis .................................................................................................. 123 
6.2.2.2. Galactosylation of negatively-charged peptide ...................................................... 123 
6.2.2.3. Ligand coating of cationic micellar nanoparticles................................................. 124 
6.2.2.4. Particle size and zeta potential measurement ........................................................ 125 
6.2.2.5. DNA retardation assay ......................................................................................... 125 
6.2.2.6. Cell culture .......................................................................................................... 126 
6.2.2.7. In vitro cytotoxicity and transfection..................................................................... 126 
6.2.2.8. Targeted simultaneous delivery of p53 and doxorubicin ........................................ 127 
6.3. RESULTS AND DISCUSSIONS............................................................................................ 127 
6.3.1. Peptide synthesis and galactosylation........................................................................ 127 
6.3.2. Particle size and Zeta potential measurements........................................................... 128 
6.3.3. Effect of ligand adsorption on DNA binding .............................................................. 129 
6.3.4. Effect of ligand adsorption on the cytotoxicity of DNA/peptide complex ..................... 130 
6.3.5. Effect of ligand adsorption on transgene expression .................................................. 132 
6.3.6. Targeted simultaneous delivery of p53 and doxorubicin............................................. 132 
6.4. CONCLUSIONS................................................................................................................ 134 
VII. CONCLUSION AND RECOMMENDATIONS FOR FUTURE WORKS..................... 137 
7.1. CONCLUSION ................................................................................................................. 137 
7.2. RECOMMENDATIONS FOR FUTURE WORKS ...................................................................... 139 
REFERENCES .............................................................................................................................. 142 
APPENDIX .................................................................................................................................... 150 
 
 
  vi 
SUMMARY 
 
Development of biomaterials for delivery of therapeutics molecules, including 
small chemical drugs and macromolecular nucleic acids/protein drugs are emerging 
from the past few decades. Ideally such carrier materials should be biodegradable, non-
cytotoxic, non-immunogenic, and at the same time able to deliver the drug molecules 
to its therapeutic sites to release its effect.  
This thesis focuses on the development of self-assembled amphiphilic 
oligopeptides forming core-shell nanostructures for efficient delivery of genes and/or 
drugs. The first part of this thesis was aimed to design an efficient plasmid delivery 
vector in the form of self-assembling oligopeptide nanoparticles. Basic material 
characterizations were performed to evaluate the suitability of the materials as gene 
carrier. Its efficacy in inducing gene expression was also tested with various cell lines 
in vitro.  
Following that, systematic tailoring of the hydrophobic tail of the oligopeptides 
was demonstrated to fine-tune and achieve desired properties of the vehicle for 
simultaneous delivery of drug and gene application. Versatility of the resulting vehicle 
was demonstrated with its capability to deliver gene, drug, or both simultaneously.  
After which, simultaneous delivery of both p53-encoding plasmid and 
doxorubicin, as the anticancer agents was demonstrated with the self-assembled 
peptide carrier to attain synergistic anticancer effect in a model cancer cell line. A 
study with liver cancer HepG2 cell line showed that the combination of these 
therapeutic molecules evidently achieved increased cytotoxic effect against the cancer 
cells.  
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Finally, a method of incorporating an active targeting ligand onto cationic 
micellar nanoparticles was presented. By designing a short peptide containing a 
negatively-charged block of amino acids and a galactose moiety, electrostatic coating 
of cationic micelles containing both drug (in the core) and gene (on the surface) with 
the peptide was made possible.  
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Cancer therapy has lately gained increasing interest among material scientists, 
molecular biologists, and medical professionals. Various approaches have been 
introduced to counteract the disruptive mechanisms of the disease; the most intense 
material research activities in this health science research field can be broadly 
categorized into drug therapy and gene therapy. In cancer drug therapy, materials like 
liposomes [1-3], stimuli sensitive polymeric micelles [4-6], and microspherical 
polymeric matrices [7-9] have been introduced to deliver potent anticancer drugs into 
cancer cells at physiological conditions. The anticancer drugs introduced could be in 
the form of small molecular chemical drugs or macromolecular protein drugs [10]. 
Likewise, in gene therapy, viral-based [11] and non viral-based vehicles like 
polycations [12-14], dendrimers [15], and oligopeptides as cell penetrating carriers 
[16] have also been introduced to increase the expression of antimitotic or apoptosis-
inducing genes in tumor cells.  
Most of the above-mentioned delivery vehicle research exploits the 
characteristics of small (nano-scale) particulates to escape rapid clearance in the body, 
such as immune system clearance or kidney filtration, hence capable of prolonging the 
circulation of therapeutic materials in the blood stream. Such nano-sized particulate 
systems for drug delivery have been introduced since as early as 1974 for liposomes 
[17], and 1989 for polymeric micelles [18]. Despite the intense ongoing research in 
this area, statistical figures still shows the importance and need for more of such 
research to improve on the current technology for cancer disease therapy and 
management. Figure 1.1 summarizes the latest available statistics on the cancer 
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incident and death rates in the USA (data year from 1975-2005) from the epidemiology 
study reported by the National Cancer Institute of USA (NCI) in 2009. Even though 
the 5-year survival rate has improved significantly from 50% in 1975 to 66% in 2005, 
however, as shown in Figure 1.1, the cancer-related death rate still shows only about 
10% reduction, i.e., from 199.1 death per 100,000 cancer incidents in 1975 to 184 of 
that in 2005 [19].  Moreover, taking into account the cancer mortality rate divided by 
the cancer incident rate in both years, i.e., ~39% in 1975 vs. ~49% in 2005, one could 
gauge the improvement made by the progress of cancer disease management strategies 
available in clinic over the past 30 years.  This figure indeed still show some rooms for 




























Figure 1.1 US Cancer Incidence and Mortality Rates from NCI 1975-2005 Epidemiology Study, 
reproduced with permission from [19] 
 
 
Self-Assembled Oligopeptide Nanostructures for      Chapter 1 




1.2. Objective and Scope of the Works 
The major focus on material development for cancer therapy is heavily placed 
on synthesizing highly efficient encapsulating/compacting materials to allow safe 
delivery of therapeutic agents – drugs and/or genes – into the target tumor cells in 
vitro, with minimal side effects suffered by the other healthy cells. The aim of this 
study is to design and develop biocompatible micelles self-assembled from 
amphiphilic oligopeptides for anticancer drug and gene delivery. Since cancer gene 
therapy can be broadly classified into two families: viral and non-viral, it is within the 
interest of the work presented in this thesis that only non-viral gene therapy systems 
will be considered. 
Based on current research activities in the field of cancer drug and gene therapy 
and their existing issues, the scope of this project was aimed at the following aspects: 
 
1.2.1. Design and Synthesis of new biocompatible delivery vehicles for safe and 
efficient drug and/or gene therapy 
New biodegradable amphiphilic peptides were designed and synthesized to 
form micellar nanoparticles. Amphiphilic oligopeptide sequences were designed by 
tailoring the amino acid composition to provide desired mechanism to either 
encapsulate drugs or bind DNA molecules. Characterizations of self-assembled 
nanoparticles were performed to confirm and analyze the properties of the micellar 
nanoparticles. In vitro cell culture studies were also performed to evaluate the efficacy 
of these synthetic peptide sequences for carrying therapeutic molecules into the target 
cells. 
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1.2.2. Physicochemical characterization and the structure-activity relationship 
establishment of the amphiphilic peptide sequence to allow for simultaneous 
drug and gene delivery 
Another important aspect of the project was to analyze and elucidate the 
influence of peptide charge density and hydrophobicity of the designer’s peptide 
sequences on the physical and biological activities of the carriers. Reasonable 
variations of some of these parameters on the amphiphilic peptide sequences were 
performed to investigate their effects on micellar/nanoparticle properties. This includes 
Critical Micelle Concentration (CMC), particle size, zeta potentials, as well as 
therapeutic incorporation capacity, such as drug entrapment efficiency, drug release 
profile, and gene binding capacity.  
 
1.2.3. Investigation on the co-delivery of anticancer drugs and genes for improved 
cancer therapy 
As cancer is recently discovered to be a genetic disease, which constitutes the 
alteration of the genome of cancer cells, part of this project is also dedicated to 
investigate the possibility of inhibiting cancer growth through simultaneous delivery of 
anticancer drugs and genes. A combination of p53-encoding plasmid DNA and 
doxorubicin was used for this study against proliferation of human liver carcinoma 
(HepG2) model cell line. 
 
1.2.4. Development of targeted cationic micelle system to achieve targeted co-delivery 
Targeted delivery of bioactive/therapeutic molecules to specific sites always 
remained as one of the main goals in delivery vehicle design. The last objective of this 
project was dedicated to investigate a non-covalent strategy of incorporating a 
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targeting ligand onto cationic micelles for targeted simultaneous delivery of drugs and 
genes to cancer cells. Galactose was chosen as the targeting ligand as it has been well 
demonstrated to bind the Asiaglycoprotein receptors (ASGPR) overexpressed in liver 
cancer cells. The concept of electrostatic coating concept was chosen as a rather novel 
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II. LITERATURE REVIEWS 
 
Advances in science and technology have reached an era for molecular design 
of carrier molecules for drug and/or gene delivery for therapies in many different 
fields. One particular application is in the field of cancer therapy. It has been widely 
known that many types of cancers were developed due to genetic disorder. Normal 
cells are transformed to attaining neoplastic behavior through mutations of its original 
genetic material. Genomic instability is a common phenomenon observed in cancer 
cells, when its genome changes progressively as it proliferates and introduces more 
mutations to the original genome. At the phenotypic level, this leads to a progressive 
loss of regulated cell proliferation, increased invasiveness, and increased metastatic 
potential. [20] Such cells are notoriously difficult to eradicate owing to the 
unpredictability of the metastatic location of the resulting secondary tumors. The 
ultimate objective of the design of these carrier molecules is to mediate efficient 
targeted delivery of the therapeutic materials to target cells/organs without losing their 
therapeutic capabilities, and obviously, with minimal side effects and immunogenic 
responses.  
In this chapter, a review on material developments for such therapeutic 
applications will be presented. Brief properties of cancers, which are often used as 
therapeutic targets, will first be established. Following that, fundamental understanding 
of the physiological barriers in cancer drug and gene therapy will be described. 
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2.1. Brief Discussion on General Hallmarks of Cancers 
As briefly mentioned earlier, cancer attains its phenotypic characteristics due to 
alterations of the cell’s original genetic material. Normal cells undergo reproductive 
cycles to balance cell deaths and proliferations through sets of precisely controlled 
mechanisms during the cell cycle. This cycle is briefly depicted in Figure 2.1 (a).  A 
single parent cell will divide into two identical daughter cells through several phases in 
one cell cycle, namely G1 (Gap 1), S (Synthesis), G2, and M (Mitosis). Under normal 
circumstances, when there is no demand for cell division, cells stay at its 
quiescent/senescent state, or also known as G0 phase. Within the cell cycle, there exist 
two main checkpoints that ensure that damaged or incomplete DNA will not be passed 
on to the daughter cells, namely G1/S and G2/M checkpoints. One of the important 
proteins that regulates these checkpoints is p53 tumor suppressor protein. At the G1/S 
checkpoint, DNA damages were checked and repaired upon damage recognition, 
through elevation of p53 protein. Similarly, at G2/M checkpoint, a final check takes 
place to ensure that mistakes from DNA replication during its preceding S phase are 
repaired before the cell enters M (cell division) phase.  The role of p53 tumor 
suppressor gene as the “guardian of the genome” is reflected through the G1/S 
checkpoint. Under normal (stress-free) cells, p53 protein forms a complex with mdm2 
protein that prevents it from entering the cell nucleus to perform its function, and 
remained at the cytosol. As such, p53 levels in the normal cell are low by its short half-
life nature owing to continuous degradation by proteosome in the cytosol. During the 
time of cellular insults, several cellular pathways lead to dissociation of the p53-mdm2 
complex and subsequent activation of the p53 proteins. This is marked by increased 
half-life and protein levels in the cells, allowing it to induce cell cycle arrest (at G1/S 
checkpoint) to allow for repair of damaged DNA, or to induce apoptosis (programmed 
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cell death) if the damage caused by the insults were beyond repair [20]. How p53 












Figure 2.1 (a) Cell cycle phases, adopted from [21]; (b) Hallmarks of Cancers, reproduced with 
permission from [22]. 
 
It has been reported that more than 50% of cancer occurrences have mutated 
p53 genes [23]. Due to this, the fidelity of the genome of cancer cells might be affected 
after each cell division, which results in genomic instability due to defective repair 
mechanism to handle normally occurring DNA damage [24]. Such and other causes of 
genotypic alterations in cancer cells eventually results in phenotypic characteristics of 
cancers, which can be broadly classified into 6 hallmarks of cancers summarized in 
Figure 2.1 (b) [22]. Briefly, these hallmarks include self-sufficiency in growth signals, 
insensitivity to anti-growth signals, evading apoptosis, tissue invasion and metastasis, 
limitless replicative potentials (immortality), and sustained angiogenesis. Some of 
these traits of cancers have been exploited as a therapeutic target for treating cancer. 
(a) (b) 
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For example, sustained angiogenesis requires cancer cells to recruit blood vessels at 
their surroundings in order to form a solid tumor. This trait has been targeted for 
antiangiogenesis therapy and for targeting anticancer drugs to cancer sites with 
Vascular Endothelial Growth Factors (VEGF). In addition, because of this sustained 
angiogenesis property of cancer cells, blood vessels surrounding solid tumor sites are 
mostly leaky [25, 26]. This has also been used as a strategy to carry anticancer agents 
in the form of small (nano-sized) particulates, which could passively target these leaky 
vasculatures [27, 28]. Another example of a cancer property that has been exploited as 
a therapeutic strategy is possibly related to its limitless proliferative potentials. This 
phenomenon significantly increases the metabolic rate of the cancer cells to support 
high turnover requirement for metabolite building blocks to support cell reproduction 
machineries. As such, productions of acidic metabolic wastes are increased, translating 
to acidic extracellular environment of cancer sites [29, 30]. Further, high rates of 
metabolism not only increase acidity, but also increase the temperature at cancer sites 
[31]. As such, the later generations of polymeric nanoparticles have been focused on 
tailoring multi-functionalities that respond to external stimuli, such as pH and 
temperature, to trigger drug release. This provides a mechanism for controlled release, 
which will be discussed in more details in the following sections.  
Even though recent studies of cancer biology have revealed many important 
characteristics of cancer cells, however, cancer still is a difficult disease to tackle. 
Until the year of 2002, it is still ranked as the second highest cause of death globally 
after cardiovascular disease under the category of non-communicable diseases [32]. 
This fact therefore makes research in cancer chemotherapy become ever more 
important to provide hope and avenue for better therapeutic approaches in the future. 
The following sections in this chapter will deal with review of recent and/or important 
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literature in delivery of anticancer therapeutics, its challenges, and the various 
technologies for overcoming it. Anticancer therapeutics considered in these sections 
includes both drugs and genes, as it is within the interest of the work presented in this 
thesis, i.e., to develop a carrier for simultaneous delivery of drug and gene.  
 
2.2. Overview of Cancer Drug and Gene Delivery Barriers 
In vivo delivery of drug and gene presents somewhat similar physiological 
challenges. Self-assembled polymers have been re-established widely for a carrier of 
anticancer drugs since 1990’s [33]. Such self assembly into the nano scale has gotten a 
rising attention recently due to its promising ability to prolong blood circulation of 
hydrophobic anticancer agents while passively targeting leaky cancer sites [34, 35]. In 
1986, H. Maeda reported that protein-conjugated polymer nanoparticles made from 
random copolymer of polystyrene and poly(maleic acid) with a size ranging between 
20-100 nm were circulated longer in the blood stream than the non-conjugated protein 
counterpart hence increasing bioavailability of the contained therapeutics [27, 28]. At 
the same time, as a result of the leaky angiogenic tumor vasculatures, these 
nanoparticles were able to extravasate and penetrate into tumor tissues, increasing its 
tumor/blood concentration ratio, which is also known as the Enhanced Permeability 
and Retention (EPR) effect. The finding of EPR effect brings about the concept of 
passive targeting of anticancer drugs due to the capability of polymer micelles to 
accumulate drugs at the tumor tissues up to 100 times more than in other tissues of the 
body. It was also reported that the extent of tumor extravasation varied, depending on 
the type of tumors, i.e. based on the difference in the opening of the interendothelial 
gap junctions in the lining of the tumor tissue vasculatures for different tumor tissues 
[25]. In a liver tumor model studied earlier, the cutoff pore size of such extravasations’ 
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pathways has been reported to be in the range of 400-600 nm [26]. But in other studies, 
nano-sized polymer micelles with diameters less than 200 nm were reported to be more 
suitable carriers to carry therapeutics into tumor tissues [36, 37]. Figure 2.2 
summarizes the common pathways for drug/gene entries into cancer cells. In view of 
these pathways for in vivo therapeutic delivery, physiological barriers that exist include 
non-specific uptake by mononuclear phagocytes, macrophages and reticulo-endothelial 
system (RES) in the blood and major organs, degradation (mainly for non-chemical 
drugs), extracellular diffusion, uptake across the cell membrane, release from the endo-
lysosomes, and targeting to their pharmacological sites at the cytosol, intracellular 
organelles, or nucleus. In addition, challenges like tumor-targeting ability of the vector, 
biodegradability of the polymers, and biophysical and/or colloidal stability of the 
particulate delivery systems in vivo also represents the similar extracellular barriers of 
the two therapeutic delivery systems. Detailed discussion of more specific challenges 
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Figure 2.2 Self-assembled polymer nanostructure delivery strategy to overcome extracellular and 
intracellular physiological barriers in delivery of therapeutics. (a) Polymer micelles help in escaping the 
recognition by clearance systems to prolong the blood circulation of therapeutics; (b) Nanosized 
particles allow for extravasation through the leaky tumor vasculature; (c) Small nanoparticles also 
enhance diffusion and penetration across tumor insterstice, allowing for deep distribution of therapeutics 
in tumor tissues; (d) Non-specific or (e) specific receptor-mediated endocytosis, allowing for uptake of 
therapeutics by tumor cells; (f) pH responsive micelles allow for intracellular drug release or buffering 
capacity to release micelle/gene or protein complexes; (g) Release of protein/siRNA at the cytosol or 
target cellular organelles; (h) Nuclear entries of DNA for achieving expression of therapeutic proteins. 
 
2.2.1. Overview on Challenges on Cancer Drug Therapy. 
Many of the FDA-approved small molecular anticancer drugs are hydrophobic 
and/or polycyclic in nature. In addition, they are also highly toxic to noncancerous 
cells. For these reasons, drug solubility, bioavailability in blood plasma, and targeted 
accumulation at tumor tissues are the main challenges in drug administration for 
chemotherapy. Poorly water-soluble drugs can easily lead to systemic cytotoxicity 
owing to its high affinity towards lipid cell membrane without any cell specificity and 
opsonization. It can also result in instantaneous aggregation of these drugs upon 
administration into the blood stream, which may cause subsequent serious problems 
such as embolism [37]. Furthermore, owing to the systemic distribution of 
hydrophobic drugs at various sites upon administration, as well as its aggregation in 
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to reach the target site that requires drug actions. Therefore, it is necessary to solubilize 
the drugs in a carrier to improve their bioavailability and targeting ability, as well as to 
reduce their systemic toxicity. Micellization of those biologically active small 
molecular drugs with surfactants or amphiphilic co-polymers thus offers a notable 
solution in increasing the bioavailability of the therapeutic drugs by increasing the 
solubility of the drugs in blood plasma. These systems face a challenging hurdle for in 
vivo application as the stability of the micellar system is highly dependent on the 
critical aggregation concentration of the surfactant molecules/polymer, referred to as 
Critical Micelle Concentration (CMC). For safe in vivo applications, the micelle 
vehicle should have low toxicity, low immunologic response, as well as low CMC to 
ensure stable particulate-delivery system under huge extent of dilution by blood 
volume upon intravenous injection to the host organism.  
In addition to that mentioned earlier, the micelle delivery system should also be 
able to target transformed cells in the body where the therapeutic effect of the drug is 
needed. This targeting ability contributes to the important characteristic that the 
anticancer drug vehicle should possess owing to the high toxicity nature of most 
anticancer drugs, and to prevent the drugs from exerting its toxic effect on healthy 
cells. Targeting of anticancer drugs can be classified into active and passive targeting. 
It has been reported that passive targeting of nano-scale particles by extravasating out 
from the blood vessel to the tumor sites form the first line of targeting as only particles 
having this capabilities could be recognized by cancer cells through targeting ligand 
(active targeting) recognition [34, 35].  
Many strategies have been employed in creating intelligent drug delivery 
vehicle for cancer therapy, which includes the Enhanced Permeability and Retention 
(EPR) strategy for passive targeting, ligand attachment to the vehicle to induce cancer 
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cell recognition, use of stimuli-responsive polymeric backbone to provide controlled 
release mechanism, as well as surface modification to provide masking of the drug 
delivery vehicle from opsonization-mediated phagocytosis removal from systemic 
circulation. All these strategies will be reviewed in more details in Section 2.3.  
 
2.2.2. Overview on Challenges in Cancer Gene Therapy. 
Similar to the drug delivery systems, nano-particulate gene delivery systems 
also face extracellular challenges like biodegradability, targeting ability towards cancer 
cells, structural stability of the particulate system upon intravenous injection to the 
body, as well as prolonged circulation time in systemic circulatory system with no side 
reactions with certain protein and/or phagocytic cells in the blood. Those properties are 
desired for a good gene delivery vehicle. 
Additional to those requirements, owing to the different natures of the 
therapeutic materials being transported, there exist other intracellular challenges to be 
faced by gene delivery vehicles. Firstly, release of therapeutic nucleic acid materials 
into the blood stream in an uncontrolled manner is undesirable due to its sensitivity 
towards degradation by nucleases present in the blood serum. Therefore, since nucleic 
acid materials bear net negative surface charge, a net positively charged polymer is 
required to condense the foreign DNA materials, more commonly known as complex 
formation; this constitutes to the first intracellular challenges of a gene delivery 
system.  
Subsequent challenges specific to gene delivery are focused more towards the 
intracellular trafficking mechanisms of the complex to reach the cell nucleus where 
those genetic materials can function and exert their therapeutic effects. Figure 2.3 
summarizes the presence of these challenges, which include: (a) endocytosis uptake of 
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the gene-vector complex, followed by (b) rupture of endosome membrane releasing the 
complex to cytosol, whereby it can travel towards the nucleus and at the same time (c) 
allowing decomplexation of the genetic materials to allow for (d) its diffusion across 
the Nuclear Pore Complex (NPC). As only genes transferred into the nucleus are able 
to be transcribed into mRNA for protein translation, decomplexation of these genes 
from its carrier appear to be as important as the other steps to allow for diffusion 
across NPC’s [38]. Even though all these steps only formed the current underlying 
hypothesis on the complicated mechanisms involved in delivering foreign genetic 
materials into the cell nucleus, it had been reported that all these steps seemed to be 
necessary for successful gene delivery. Research activities have been put in to 
synthesize intelligent materials that mimic virus particles to address these challenges. 




Figure 2.3 Schematic drawing on the intracellular challenges in non-viral gene delivery systems, 
reproduced with permission from [38]. 
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2.3. Current Technologies for Micellar Cancer Drug Delivery 
Many types of polymer drug carrier systems have been proposed, namely 
polymeric monolithic system, polymeric reservoir system, hydrogel system, polymer-
drug conjugate system, microsphere system, and nanoparticulate system and polymer 
micelle system. For the purpose of this thesis, the discussion shall be focused on 
polymer micelle system. Polymer micelles system will first be introduced. Following 
that, brief micelle fabrication techniques and its structural relationship will be 
reviewed. Lastly, the review on current cancer drug therapy will be wrapped up with 
the current targeting strategies. 
 
2.3.1. Introduction to Polymeric Micelles. 
Polymer micelles were first introduced as a drug carrier in 1989 [18]. It 
represents the so-called colloidal dispersions that belong to a large family of dispersed 
systems consisting of particulate matter or dispersed phase, distributed within a 
continuous phase or dispersion medium [39]. Polymer micelles normally self-assemble 
from amphiphilic block or random co-polymers. Two forces co-exist in the formation 
of micelles; one is the attractive force, which is responsible for the assembly of 
molecules. The other is the repulsive force that will prevent unlimited growth of the 
micelles. Amphiphilic copolymers will tend to self assemble when put into a 
dispersion medium in that only either its hydrophilic or hydrophobic blocks are 
soluble. When the dispersion medium are aqueous phase, the micelles are formed with 
a hydrophilic shell and a hydrophobic core at a concentration above its CMC, through 
hydrophobic interactions between the hydrophobic segments of the polymer, as well as 
through solvation and steric repulsion among the hydrophilic segments of the polymer.  
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Polymer micelles impart an interesting characteristic for in vivo applications of 
drug carriers as its size ideally ranges between 50 and 100nm [39]. This appealing 
characteristic allows polymer micelles carrying hydrophobic anticancer drugs inside its 
core to selectively target inflamed regions with leaky vasculature in cancer sites. In 
fact, the amphiphilic polymer micelle system was proposed in the field of cancer drug 
therapy through an attempt to improve upon nanoparticulate carrier system, whereby 
nano-scale shell were formulated from materials like lipid (in lyposomes) or polymers 
to encapsulate drugs in the form of nanospheres through O/W or W/O/W emulsion 
techniques [40].  
Even though the application of polymer micelle system in cancer drug therapy 
becomes very appealing owing to its suitable characteristics as drug carrier, there are 
still some other parameters to be considered. These include CMC, drug loading 
capacity, physical stability and drug release profile from the micelles system. 
Therefore, in the next three sections, micelle fabrication and its structure, drug 
solubilization into micellar core, as well as its physical stability will be reviewed. 
 
2.3.2. Micellization. 
It is widely accepted that micelle structure is generally affected by two factors, 
i.e., micelle fabrication and chemical composition of polymer chain. Methods of 
micelle fabrication can be divided into two groups, namely direct dissolution method 
and dialysis method. The choice of either method is generally based on the building 
blocks of the micelle system; that with strong hydrophobic tails like cholesterol, long 
alkyl group, or fatty acids, and hence poor water solubility, are generally fabricated 
through a slow self-assembly method, like dialysis. On the other hand, more water 
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soluble amphiphilic polymers are generally fabricated into micelles via direct 
dissolution method.  
As the name suggests, in direct dissolution method, both 
hydrophobic/amphiphilic drug and amphiphilic copolymer are directly solubilized in 
an aqueous phase at room temperature or elevated temperature and at a concentration 
above its CMC. In contrast, in dialysis method, both hydrophobic drug and 
amphiphilic copolymer are firstly dissolved in organic medium, such as 
dimethylsulfoxide (DMSO), dimethylformamide (DMF), tetrahydrofuran (THF), or 
acetonitrile, at certain composition. Following that, the resulting drug-polymer solution 
is subjected to solvent exchange through dialysis membrane against aqueous phase to 
induce the micelle formation.  
Amphiphilic molecules with a balanced hydrophobic and hydrophilic segment 
ensure the formation of core/shell structured micelles in the aqueous solution. As a 
first guiding principle in designing a new polymer micelle system, an empirical model 
proposed by Griffin (Equation 2.1) for the prediction of non-ionic surfactant molecule 
aggregation behaviour as a function of molecular weights of both hydrophobic and 
hydrophilic segments is useful [41, 42]. 
20´=
M
MHLB h   (Eq 2.1) 
Griffin’s definition of HLB scales the molecular weight ratio of the hydrophilic 
segment (Mh) to the whole amphiphile (M) from 0 to 20, with 20 being entirely 
hydrophilic. For small molecular non-ionic surfactants, a typical value of 10-18 on the 
scale is defined to be suitable for the amphiphilic molecules to function as solubilizer 
of hydrophobic substances in an aqueous solution [41, 42]. In the context of micelles 
formed from amphiphilic copolymers, the typical HLB values are calculated and listed 
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in Table 2.1, which range between 5 and 19, wider than that of non-ionic surfactant 
systems. Intuitively, as the HLB scales get closer towards the hydrophobic extreme, 
i.e. HLB=0, the CMC is reduced. However, when making comparison between 
different polymer backbones, it is important to make a comparison between molecules 
having similar types of hydrophobic interactions, as the model does not include 
parameters defining the types of intermolecular interactions such as hydrogen bonding, 
stereocomplexation, charge transfer or polyelectrolyte complexation. For example, 
molecules having p-p interactions are known to have lower CMC values compared to 
molecules having similar HLB but assembled through hydrophobic interactions 
between aliphatic chains. Some examples on the effect of HLB on the resulting 
micellar aggregates are listed in Table 2.1 [6, 43-54]. In addition, stereocomplexation 
lowers the CMC value of amphiphilic copolymers with similar lengths of hydrophobic 
and hydrophilic blocks [55, 56]. Therefore, this model should be used only as a first 
degree of estimation in designing a balanced amphiphilic self-assembled micelle 
system. Measuring CMC value is a more direct way to evaluate the micellization 
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2.3.3. Drug Solubilization into micellar core. 
Apart from micellization, which is characterized by the existence of its CMC, 
drug solubilization forms another important aspect in the design of polymer micelles. 
Solubilization of drugs into the micellar core occurs as the spontaneous formation of 
hydrophobic environment of micellar core provides high affinity towards hydrophobic 
drugs. If the drug and the hydrophobic block of the copolymer have a similar 
molecular structure, the efficiency of drug encapsulation can be determined through 
the drug-polymer compatibility, which can be predicted by the interaction parameters 
defined by Flory-Huggins [57] (Equation 2.2): 
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2ddc -=   (Eq 2.2) 
Where csp represents the interaction parameter between the drug (s, solubilizate) and 
the core-forming polymer (p). Small value of csp indicates better compatibility between 
the drug and the core-forming polymer. ds and dp are the Scatchard-Hildebrand 
solubility parameters of the drug and polymer, respectively, which indicate 
intermolecular interactions contributied by Van der waals dispersion forces, dipole-
dipole interactions, and hydrogen bonding, and can be obtained from experiments or 
estimated using the group contribution method. Vs is the molar volume of the drug. 
Simple prediction using such interaction parameters has been well-demonstrated in the 
systems of ellipticine (an anticancer drug) and poly(β-benzyl L-aspartate) or poly(ε-
caprolactone) (PCL) or poly(d,l-lactide) or poly(glycolide) by Liu and co-workers 
[58]. In this model, stereocomplexation, charge transfer and polyelectrolyte 
complexation have not been taken into consideration. Therefore, cautions need to be 
taken when applying this model to predict the compatibility between drug and 
amphiphilic copolymers for drug encapsulation based on these types of molecular 
interactions. Being inspired by this model, one can design the backbone of the 
hydrophobic segment of polymer with corresponding functionalities based on the 
molecular structure of specific drugs to achieve high encapsulation efficiency. As such, 
there would be no single universal drug carrier that is able to entrap all types of drugs 
efficiently. Examples of polymers with different hydrophobic blocks with their 
corresponding drug loading and encapsulation efficiency reported in the literature are 
summarized in Table 2.1.  
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2.3.4. Micelle stability. 
Since micellization is a dynamic phenomenon, one important practical issue 
with using micelles as delivery vehicles is its stability upon dilution. Once 
administered into the body, the micelles carrying hydrophobic drugs undergo infinite 
dilution by the blood. It is therefore required that the micelles should not disintegrate 
quickly after experiencing such a huge extent of dilution. For this reason, CMC 
becomes an important characteristic of micellar drug delivery systems, and thus lower 
CMC value is more desirable. Liu et al reported a thorough investigation on the in vivo 
fate of micelles self-assembled from mPEG-b-PCL block copolymer [59]. Since the 
hydrophobic core was formed from semi-crystalline PCL, 74% of the micelle 
aggregates were found in the blood stream after 24 hours of circulation. Interestingly, 
although the micelles with the PCL core were administered to mice at a concentration 
such that its concentration would fall two-fold below the CMC upon dilution with the 
mice blood volume, about 55% of the intact micelles were still circulated in the blood 
at 24 hours post-injection. This finding not only signified the importance of CMC in 
determining the in vivo fate of micelles, but also the importance of intermolecular 
interactions between the unimers of the micelles. 
Various studies on polymer micelle drug delivery vehicles have been 
performed with different polymer backbones. Various amphiphilic copolymers with 
hydrophilic block made of poly(ethylene glycol) (PEG), poly(L-lysine) (PLL) or 
polysaccharide and hydrophobic block made of poly(L-lactide) (PLLA), poly(D-
lactide) (PDLA), poly(lactide-co-glycolide) (PLGA), poly(aspartic acid), poly(b-
benzyl-L-aspartate) have been reported. The micelles formed from these copolymers 
have CMC values ranging from less than one mg/L to hundreds of mg/L. Several 
approaches have been made to reduce the CMC and increase micelle stability. This can 
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be classified into two categories, i.e. non-covalent and covalent interactions. Non-
covalent interactions include hydrogen bonding, p-p stacking core-stabilization [60, 
61], metal-ligand interaction [62], and interpolyelectrolyte core-locking [63]. Covalent 
interactions include core-[64], and shell-cross linking [65]. Cross-linkable functional 
groups such as methacrylates or carboxylic acid groups can be introduced into the core 
[64, 66]  and shell [67]. Methacrylate-based functional groups in the micellar cores 
were cross-linked by thermal polymerization [66], UV-irradiation [68], or Michael 
addition with multifunctional thiol compounds [69]. Carboxylic acid groups-based 
functional groups in micellar cores or shells in polypeptides such as poly(aspartic acid) 
can be cross-linked with water-soluble carbodiimide in the presence of diamine [70] or 
glutaraldehyde [71] cross-linkers. Cross-linking of micelles has successfully ensured 
their integrity and stability in vivo. However, new issues may arise with this approach. 
For example, cross-linking conditions may affect the fidelity of drug molecules, and 
drug release mechanism and rate from the micelles may be changed after cross-linking. 
 
2.3.5. Functional micelles. 
A number of functional polymer micelle systems have been developed to 
overcome extracellular and intracellular barriers for anticancer drug delivery. It was 
reported that due to high rate of glycolysis in tumor tissues, the external pH of 
cancerous tissues tend to be lower than that of the surrounding normal tissues [72]. 
Tumor aggressiveness has been consistently correlated to the increase in glucose 
uptake [29], which in turn increases glucose metabolism inside the cells. Both aerobic 
and anaerobic respiration following the glycoslysis process produce acid byproducts 
(H+ in the case of aerobic, and lactic acid in the case of anaerobic), which are then 
transported out to the extracellular environment of the cells, hence reducing the 
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extracellular pH of the tumor tissue [30]. At the same time, cancerous tissues were also 
reported to have an increased temperature compared to the surrounding healthy tissues, 
owing to the high metabolic activities [31]. The release of drugs from the endosomes 
or lysosomes into the cytosol is also important to achieve high efficiency in killing 
cancer cells when the micelles are used as a carrier. Therefore, various functional 
groups were added to the polymeric backbone of the micelles to introduce sensitivity 
towards external stimuli that respond to the physiological pH and cancerous tissues’ 
external pH and temperature.  
A number of approaches were reported to introduce pH sensitivity to polymer 
micelles for pH-induced drug release. For example, an acid-labile linker such as 
hydrazone was used to covalently attach the anticancer drug, doxorubicin, to the 
carriers PEG-b-poly(aspartic acid) grafted with doxorubicin via hydrazone linker. The 
linker was reported to be mostly stable at physiological pH of 7.4, but cleave 
selectively at reduced pH of around 5-6 in the endosomes [73]. Similarly, Frechet’s 
team used a mildly acid-labile cyclic benzyldene acetal linker to conjugate the 
hydrophobic aromatic benzyldene groups onto the poly(aspartic acid) block or PEO-b-
poly(aspartic acid) block copolymer. At pH 5, this linker underwent rapid hydrolysis, 
with a half-life of 60 minutes at 37ºC. Upon hydrolysis of the acetal linkers, the 
hydrophobic groups were cleaved from the copolymer chain and the micellar 
assemblies were disrupted; this further triggered the hydrophobic drug release from the 
micelles [74]. In another manner, protonable functional groups can also be introduced 
to the polymer backbone to break the hydrophobic-hydrophilic balance of the micelles 
upon protonation of these groups at reduced pH. For example, Lee et al reported pH-
sensitive micelles formed from block copolymers of PEG and poly(histidine) [75]  At 
the normal physiological pH of 7.4, poly(histidine) was hydrophobic, which formed 
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the core of the micelles. However, at lower tumor extracellular pH or at endosomal 
compartments, histidine groups would be protonated. Therefore, the hydrophobic 
block of the polymer became hydrophilic, disintegrating the core/shell structure of the 
micelles and thus releasing the enclosed doxorubicin molecules. In other studies, 
poly(undecenoic acid) [5, 52, 54] has also been used as the pH sensitive segment to 
form functional micelles by utilizing the protonability of the carboxylic acid groups. In 
contrast to poly(histidine), the polymer segment containing carboxylic acid groups 
becomes more hydrophobic when protonated in acidic environments, causing the 
polymer micelles structure to collapse, which leads to drug release.  
Recently, Soppimath et al has also proposed the use pH-induced temperature 
sensitive polymers to form functional micelles for targeted intracellular delivery of 
anticancer drugs such as paclitaxel (PTX) and doxorubicin. The first polymer reported 
was a random copolymer of N-isopropylacrylamide (NIPAAm), N,N-
dimethylacrylamide (DMAAm) and undecenoic acid (P(NIPAAm-co-DMAAm-co-
UA)) [52, 54]. PNIPAAm is a temperature-sensitive polymer, having a lower critical 
solution temperature (LCST) of about 32°C in water. At temperatures below its LCST, 
PNIPAAm is water soluble, but it becomes water insoluble at temperatures above its 
LCST. DMAAm is more hydrophilic than NIPAAm, and was incorporated to adjust 
the LCST of the polymer to be slightly higher than the body temperature (37°C). 
P(NIPAAm-co-DMAAm-co-UA) formed micelles at pH 7.4 and 37°C, which had a 
hydrophilic P(NIPAAm-co-DMAAm) shell and a hydrophobic UA core. At low pH 
(e.g. 5.0 or 6.6), UA became hydrophobic due to its protonation, decreasing the LCST 
of the polymer and thus leading to the collapse of the core/shell structure of the 
micelles at 37°C. Doxorubicin was loaded into the micelles. Doxorubicin release from 
the micelles was also pH-sensitive. At pH 7.4, the drug release was slow. However at 
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pH 5.0 or 6.6, the drug release was much faster due to the deformation of the core/shell 
structure. A pH-induced temperature-sensitive block copolymer based on UA and 
NIPAAm was synthesized to narrow the size distribution of the micelles. A cholesterol 
molecule was conjugated onto one UA molecule of P(NIPAAm-co-DMAAm-co-UA) 
to increase the hydrophobicity of the polymer, and paclitaxel was loaded into the 
micelles. Paclitaxel release from the micelles was also pH-sensitive, being faster at pH 
5 and 6.6 when compared to pH 7.4.  From confocal microscopic studies using DOX 
as a model drug, a significantly large amount of DOX molecules were transported into 
the cell nucleus when delivered by the pH-induced temperature-sensitive micelles, 
whereas the majority of the DOX molecules were located in the cytosol when 
P(NIPAAm-co-DMAAm)-b-poly(lactide-co-glycolide) micelles without pH-sensitivity 
were used as the carrier.  
In addition, micelles containing disulfide bond, which is responsive to 
reduction by the elevated level of glutathione molecules inside the cells were also 
proposed to achieve intracellular drug release [76]. Upon internalization of these 
micelles, high glutathione level inside the cells allows for digestion of disulfide bond 
linkage, hence releasing the attached drug or degrading the polymeric backbones. 
Moreover, the use of biological ligands attached onto the surface of the 
micelles for active drug targeting has received increasing attention in the field [34]. 
For example, micelles coated with monoclonal antibody on the surface [77], or with 
small molecular targeting compounds such as folic acid [5, 52], galactose [78], or with 
peptides such as RGD [46], or with growth factors [79] have been reported for specific 
tumor targeting. Table 2.2 [5, 46, 77, 78, 80-87] summarizes the typical targeting 
ligands that have been used for micelle drug delivery.  
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In recent studies, multifunctional micelles were reported to carry imaging and 
therapeutic agents for simultaneous therapy and detection. For example, co-
encapsulation of anticancer drugs with hydrophobic iron oxides with RGD-
functionalized PEG-b-PLA micelles for the purpose of targeted delivery of 
doxorubicin and MRI-imaging [88], or inclusion of both superparamagnetic iron oxide 
and fluorescent quantum dots along with doxorubicin into the core of the micelles 
formed from lipid-modified PEG [89]. Such systems allow for simultaneous therapy 
and detection within a single administration.  
Table 2.2 Biological signals as active targeting ligands 
Cellular Target Targeting ligand Cancer types Ref 









Galactose Liver cancer [78] 
VEGF receptors Recombinant VEGF Most maglinant 
tumors 
[81] 



















Transferrin receptor Transferrin Most maglinant 
tumors 
[85] 




Aptamers Prostate [87] 
 
2.4. Current Technologies for Non-viral Cancer Gene Delivery 
The basic concept of gene therapy is disarmingly simple – introducing the 
gene, and its product should cure or slow down the progression of a disease [90]. The 
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capacity to correct a mutant gene within the context of the chromosome holds great 
promise as a therapy for inherited disorders but fulfilling this promise has proven to be 
challenging [91]. The future success of gene therapy will depend on the ability to 
achieve efficient expression of nucleic acids encoding therapeutic proteins following in 
vivo delivery into target cells. However, it would be unrealistic to not expect genetic 
therapies to produce side effects, especially in the context of viral-gene therapy [92]. 
Therefore, concerns about viral-induced immune reactions and the risks associated 
with replication-competent viruses have promoted interest towards non-viral 
approaches [93]. 
Nevertheless, gene therapy is an attractive approach for cancer treatments as 
cancers are believed to be caused by genetic disorders. Drug resistant phenotypes of 
many cancers have also been associated with malfunction of certain genes in the cells 
[94]. Malfunction of genes in cancer can be broadly classified as mutation/deletion of 
growth-suppressing genes, or over-expression of growth-promoting genes. In this 
context, gene delivery includes both delivery of plasmid DNA encoding therapeutic 
proteins and delivery of antisense oligonucleotides (ODN) or small interfering RNA 
(siRNA). DNA delivery aims to provide a corrective action by expressing a specific 
protein inside the cells bearing chromosomal mutation or deletion that renders its 
expressed proteins being non-functional. On the other hand, delivery of antisense ODN 
or siRNA provides a remedy for defective genes that are over-expressed inside the 
cells by interfering with (down-regulating) its mRNA-to-protein translation inside the 
cells. Although both ODN and siRNA silence gene expression at the post-
transcriptional level (often referred to as post-transcriptional gene silencing technique), 
they work in a different manner. ODN is a short single stranded DNA, which is 
complementary to the transcribed mRNA (sense sequence), and hence can bind to this 
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mRNA and prevent it from being translated into the protein inside the cells. 
Alternatively, ODNs can be targeted to bind to a splicing site of a pre mRNA, and 
aimed to modify the exon end of the mRNA [95]. siRNA, on the other hand, is a short 
double stranded RNA, which assembles into endoribonuclease-containing complexes 
upon entering cells, also known as RNA-induced silencing complex (RISC). These 
siRNA molecules then unwind inside the RISC, making it activated to recognize and 
splice its mRNA target strands in the cells, and thus down-regulating the expression of 
the target protein [96]. 
In this review section, classical materials designed for gene delivery 
application, together with the rationale behind its design will firstly be introduced. 
Following that, some strategies that are currently on trial and development to improve 
upon the classical gene delivery vectors will be discussed. 
 
2.4.1. Classical Non-Viral Gene Delivery Vehicle. 
In his review on non-viral cancer gene therapy, Akhtar classified the classical 
non-viral gene delivery vehicles into four distinct classes of materials, namely (a) 
cationic polymers, (b) dendrimers, (c) cell penetrating peptides (CPP), and (d) 
liposomes [97]. Among these four classes of materials, dendrimers are the least 
attractive class of materials owing to their intrinsically high molecular weight 
characteristics, hence inducing toxic effect in vivo. Review on the other three classes of 
materials will follow. 
2.4.1.1. Cationic polymers. 
The most widely studied polymers that belong to this group are 
polyethyleneimine (PEI) and poly(L-Lysine) (PLL). This class of materials has high 
positive charge content within the molecules, enabling them to electrostatically bind 
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foreign nucleotides, such as plasmid DNA, to form a condensed structure and hence 
protecting it from degradation by nucleases. Condensed structure resulting from 
binding of cationic polymers and nucleotides are often refered to as polyplexes. PEI 
has more frequently been used in gene delivery than PLL due to its high secondary 
amine content, and hence possessing enough buffering capacity at any pH value to 
facilitate endosomal escapes, which are often referred to as “proton sponge effect”. 
Furthermore, PLL was shown to have poorer transfection efficiency compared to its 
counterparts when used alone or without any modifications. 
PEI was firstly introduced by the work of Boussif et al as a versatile vector for 
gene and oligonuceotide transfer in 1995 [13]. Following the success of this work on 
PEI-mediated gene delivery, many works have been presented in attempts to reveal its 
underlying success mechanism. Godbey et al studied the intracellular trafficking of 
PEI/plasmid complexes using fluorescent-labeled linear PEI with average molecular 
weight (Mr) of 25 kDa and confocal microscopy. The complexes attached to the cell 
surfaces and migrated into clumps that are endocytosed. The endocytotic vesicles grow 
in number and size and are osccasionally seen to lyse [98]. PEI based complexes has 
an excellent transfection efficiency in vitro and significant transfection in vivo, and 
hence regarding non-viral cationic polymer vectors, linear PEI with an average 
molecular weight of around 22 kDa is often referred to as the ‘gold standard’ for 
efficient gene delivery.  
Although highly efficient transfection vector made from PEI are already 
available, its main problematic characteristics is its pronounced cytotoxicity both in 
vitro and in vivo, as well as its various undesired non-specific interactions with 
biological components in the blood environments. In general, cationic polymers not 
only have notable properties in binding foreign nucleic acids materials, but they also 
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bind to many other negatively-charged biological materials, such as phospholipids 
bilayer cell membranes as well as circulatory proteins in the blood plasma. Ogris et al 
reported that PEI-based complexes mediated aggregation of erythrocytes at DNA 
concentrations relevant for in vivo gene delivery. Plasma proteins such as IgM, 
fibrinogen, fibronectin and complement C3 were found to bind to non-PEGylated 
DNA complexes [99]. In addition, the toxicity of PEI was also reported to increase 
with the increasing number of positive charges, the hydrophobicity and the molocular 
wight of the polymer [100]. 
As mentioned earlier, PLL has become less attractive as compared to its 
counterparts, even though it is one of the first cationic polymers employed for gene 
delivery. The main reason is that PLL-mediated transfection often, if not always, 
requires co-application of chloroquine, a lysosomotropic agent, to achieve successful 
in vitro transfection [101]. This lysosomotropic agent is known to help in reducing the 
lysosomal degradation of lipoplexes in the intracellular vesicles upon endocytosis of 
the complex. In addition, as PLL also provide high positive charge content, similar 
non-specific interactions between polyplexes with other biological materials in vivo as 
PEI polyplexes are also faced by PLL polyplexes. 
2.4.1.2. Cell Penetrating Peptides (CPP). 
CPP belong to the class of materials made up of short peptide sequences that 
possesses biological activity. Many of these materials are actually cationic in nature. 
They are mostly derived from human pathogenic viruses, such as Human 
Immunodeficiency Virus-type 1 (HIV-1) and Simian Virus 40 (SV40) viruses [102, 
103]. Certain segments from viral protemics materials were reported to be responsible 
of its penetration across human cells during infection; it is the sequence derived from 
those segments that is used as a carrier for gene delivery purposes.  
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The most widely used CPP are derived from HIV-1 virus, called TAT peptide. 
Not only that these CPP were reported to increase cellular uptake by increasing 
binding capacity towards negatively charged cell membranes, it was also reported to 
possess nuclear localization signals (NLS) to locate the cell nucleus upon endocytosis. 
The NLS ability of this CPP, especially that of the TAT peptide, is however still in 
arguments. In a recent study by Richard et al, it was shown that TAT NLS ability of a 
sequence comprising GRKKRRYRRRPP might have actually resulted from unreal 
artifact owing to the use of fixation protocols during the imaging process. They 
reported that high density of positive charges led to rather strong binding of the 
peptides to the overall negatively charged plasma membrane; and because of mild 
fixation procedures, disruption of membrane barrier took place and caused increased 
transfer of hydrophilic probes into the cytoplasm or nucleus. Upon such disruption, 
high positive charges of the peptides most probably cause their strong binding to 
nucleic acids and ultimately lead to the accumulation of CPP into the nucleus, which is 
an abundant reservoir of cellular nucleic acids [103]. 
2.4.1.3.  Liposomes. 
The liposome class builds upon lipid-based material for delivery vehicle. 
Structurally, liposome consists of hydrophobic lipid domain, polar head-group domain, 
and a linker functionality connecting the polar-head group domain to the hydrophobic 
lipid domain. Its approach has actually been used in the earlier work for drug delivery, 
whereby nano-scale shell compartment is fabricated by creating lipid-bilayer shell with 
the hydrophobic tails of the lipid molecules being sandwiched in between two 
hydrophilic heads. However, for the gene delivery applications, the hydrophilic head 
segments often consist of polyamine moieties, amidinium, guadinium salts, or a single 
quaternary ammonium-based group to increase the cationic nature of the liposome. 
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Karmali and Chaudhuri, in their review on the effects of the hydrophobic domain 
structure on the transfection efficiency, stated that in general, lipid containing one 
hydrocarbon chain tended to transfect less efficiently and are more toxic compared to 
that containing two linear aliphatic chains. The function of the linker segment also play 
an important role in the liposome formation as it controls the conformational 
flexibility, degree of stability, biodegradability, and hence the gene transfer efficacy of 
the cationic amphiphile. The most common linker groups include ethers, esters, 
carbamates, amides, carbonates, phosphonates, and disulfides [2]. 
 
2.4.2. Poly Ionic Complex Micelle (PIC) for Non-Viral Gene Delivery Vehicle. 
Studies on PCM from block copolymer as gene delivery vehicles were first 
pioneered by Kataoka and his team with the introduction of the PIC micelle concept in 
the 1990s. In this system, polymeric macromolecules containing hydrophilic and 
cationic segments were used to condense DNA molecules. Upon condensation, 
core/shell structured micelles were formed, which have a core formed through charge 
neutralization of the oppositely-charged polymer and gene and a hydrophilic shell. 
Charge neutralization reduces interactions between the originally charged 
macromolecules and the aqueous medium, forming a hydrophobic region [104]. The 
core/shell structure formed through hydration of the hydrophilic segment of the 
polymer provides for stability of the PIC micelles in the blood, and prolongs blood 
circulation of the enclosed genes.  
Typically, the cationic polymer for PIC micelles is made up of PEG as its 
hydrophilic segment and cationic polymers or peptides such as poly(L-lysine) [105], 
poly(phosphoaromidate) [106], chitosan [107], poly(amidoamine) in both dendrimer or 
linear forms [33, 108], or polyethylenimine (PEI) [109]. The protonability of the amine 
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groups in the cationic segments is mainly determined by the nature of the amine 
groups, i.e., whether it is a primary, secondary, or tertiary amine [108, 110]. In 
addition, amine groups from different repeating units might have different pKa values, 
although it fairly falls within a narrow range for the same type of amine groups [111]. 
This, in turn, becomes the first factor that effects the complexation and 
decomplexation of genes with the polymer as well as endosomal escape mechanism of 
complexes. The uniqueness of this system is that the self-assembly of the core/shell 
structure is induced by the electrostatic interaction between the polyions. Therefore, 
the size and stability of the PIC micelles are affected by the hydrophilic/cationic 
balance [110]. Several other factors such as the length of hydrophilic and cationic 
segments, the composition of cationic segment and the nature of amine groups have 
also been demonstrated to affect these properties. In general, the size of the PIC 
micelles reduces as the hydrophilic chain length increases. This is attributed to the 
increase in steric hindrance for micelle association, resulting in less aggregation 
number [110, 112]. In addition, the size of PIC micelles generally increases as the 
length of the cationic segment increases. This is because an increased length of 
cationic segment leads to bigger charge-neutralized regions being present, increasing 
hydrophobic-hydrophobic associations between the neutralized regions. On this basis, 
it appears that long hydrophilic and short cationic chain segments are more desirable 
for the formation of PIC micelles. However, unlike the conventional micelles where 
the stability is implied directly by the CMC values, the stability of PIC micelles is an 
indirect result of the balance between hydrophilic/cationic segments. It is greatly 
affected by the presence of competing anionic macromolecules. Studies using heparin, 
a typical anionic protein present in the blood, have indicated that longer cationic and 
shorter hydrophilic chain lengths are advantageous to increase the stability of the 
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resulting PIC micelles [110, 113]. This is because the longer the cationic chain length, 
the more stable the interaction with the genes, resulting in more stable PIC micelles. 
Likewise, the excessively long hydrophilic chain length reduces the stability of the 
resulting PIC micelles in an analogous way as the increase in the hydrophilic chain 
length of conventional amphiphilic copolymers. 
 
2.4.3. Cationic Polymer Micelles for Gene Delivery Vehicle. 
Cationic micelles assembled from amphiphilic copolymers have attracted an 
increasing attention in the field of gene delivery. The first cationic micelle system 
made from poly(L-Lysine)-b-poly(lactic-co-glycolic acid) at CMC of 9.6 mg/L was 
reported as DNA delivery carrier by T. G. Park’s team in 2002 [114]. In 2004, Wen et 
al also reported a similar system made from biodegradable poly(phosphoester) [115]. 
Gene expression efficiency induced by these micelles was relatively low probably due 
to the absence of amine groups that could induce endosomal escape of DNA complex 
micelles after endocytosis. Being inspired by these studies, Wang, et.al. synthesized a 
cationic amphiphilic copolymer that contains tertiary amine groups for the “proton-
sponge” effect to induce intracellular release of genes [116]. This copolymer formed 
cationic micelles at low concentrations with CMC of below 10 mg/L.  These micelles 
delivered DNA and siRNA efficiently into various cell lines and human mesenchymal 
stem cells [117]. PEGylation of the polymer decreased gene expression efficiency, 
which depended on the length of PEG used [118]. The longer the length of PEG, the 
lower was the gene expression efficiency induced. In 2007, Qiu et al reported another 
type of cationic micelles self-assembled from PEI-graft-poly(e-caprolactone) for gene 
delivery [119]. In addition, Zhu et al reported cationic micelles formed from block 
copolymer of PEG and cationic block grafted with poly(e-caprolactone) for DNA 
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delivery [120]. PEG provided the stability of the micelle/DNA complexes. However, it 
also shielded the cationic charge and hindered DNA from interacting with the cationic 
block of the polymer. For siRNA, one strategy has been proposed by Park and his team 
with PIC micelle system to overcome charge shielding by PEG chain is to conjugate 
functional PEG onto the 5’-end of the sense strand of siRNA, instead of using PEG-
polymer conjugate. For example, PEGylation of VEGF siRNA was demonstrated to 
inhibit angiogenesis of cancer cells both in vitro and in vivo [121]. After PEGylation, 
the stability of micelle/siRNA complexes in the serum-containing medium was 
significantly improved, without compensating its binding to the cationic carrier. In this 
particular case, the efficiency of Bcl-2 downregulation in cells was found to be similar 
for both siRNA and PEG-siRNA [122]. 
 
2.4.4. Gene Delivery in Clinical Trials. 
Although tremendous efforts have been made to develop efficient non-viral 
gene delivery carriers, there are still limited clinical applications due to low gene 
transfection efficiency induced. From the latest available data updated in September 
2008, there have so far been 1472 clinical trials performed on gene therapy, among 
which 960 trials were conducted on cancer gene therapy [123]. Lipofection has been 
used for 86 clinical trials. Naked DNA has been employed in 154 clinical trials, and 
the balance has made use viral vectors. For Lipofection, 43 clinical trials adopt antigen 
and receptor immunotherapy, 17 on tumor suppressor strategy, 2 on antisense approach 
and 2 on suicide gene strategy. Since it has not been demonstrated that any non-viral 
vector can achieve 100% gene transfection efficiency, i.e. transfecting every cell with 
the target gene, cancer immunotherapy and vaccine are more promising approaches in 
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using non-viral vectors when compared to other types of cancer therapy, as it is not 
necessary in these approaches to transfect every cell with the target gene. 
For siRNA, a cyclodextrin-based cationic polymer has also recently been 
approved by FDA as a carrier to enter Phase I clinical trial. This system developed by 
Calando Pharma uses an unmodified siRNA targeting the M2 subunit of the 
ribonucleotide reductase to treat solid tumors [124]. The polymer/siRNA nanoparticles 
are modified with PEG with or without the targeting signal transferin for intravenous 
injection. In another system developed by Intradigm, a cationic peptide-based 
biodegradable polymer was used to complex VEGF-, VEGFR2- or EGFR-targeted 
siRNAs. This system has been proven to be efficient in suppressing tumor growth in 
preclinical studies [125]. RNA interference (RNAi), a new member to the gene therapy 
family, has recently gained much more attention in clinical applications than the 
conventional plasmid DNA. The major goal of gene encoding plasmid DNA is to treat 
loss of function mutations in diseases. This requires more sustained gene expression, 
which is difficult to achieve and regulate especially using non-viral vectors. In 
contrast, RNAi systems are employed mainly to treat gain of function mutations. In 
such circumstances, transient expression is sufficient. This post-transcriptional 
modulation is reversible and easier to control. Furthermore, the mechanism of RNAi 
action is better understood than the conventional gene therapy that requires unique 
regulational control over expression of different genes. While the research on 
improving the gene delivery systems still continues with limited clinical promises, the 
high specificity and potency of siRNA have attracted more scientists to explore its 
potential in clinical applications.  
 
2.4.5. Modification of Standard Non-Viral Gene Delivery Vehicle. 
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Several modification strategies have been employed to improve on the classical 
non-viral gene delivery vehicles for better and safer application in vivo.  PEGylation of 
the polymeric surface is one of the first modifications with a rationale to provide 
steric-stabilization as well as surface charge shielding, hence allowing the complex to 
interact less with the negatively charged circulatory proteins in the blood 
compartments [99]. This also helps to mask-off the complex from clearance by RES 
and MPS. In addition to this, surface modification by using cancer cells specific-
receptor recognition signals such as transferrin [99] and integrin [126], gene delivery 
in vivo can be achieved with minimal gene expression in the major organs like lungs 
and livers. 
Another strategy of modification done on the polymeric backbone is by 
hystidylation of the backbone to increase buffering capacity for endosomal rupture 
mechanisms upon internalization of the polyplexes via endocytosis. Midoux et al. in 
their study reported that the cationic polypeptide vector derived from the HA2 subunit 
of the influenza virus, when five of its amino acid residues were substituted with L-
histidine residue, achieved 10-fold increment in the trans-gene expression as compared 
to that without the histidylation [127].   
Other than backbone modification of the polymeric carriers, surface 
modification has also been reported. For the purpose of incorporating targeting ligands 
onto the surface of the nanoparticles, Green et al have reported that electrostatic 
coating could be used with reasonable degree of coating stability [128]. 
 
 
2.5. Summary and Concluding remarks 
There have been an increasing number of publications on polymer micelles for 
delivery of therapeutics (Figure 2.4), indicating that self-assembled nanostructures as 
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carriers are gaining increasing attention in the field. Design of multifunctional polymer 
micelles is on demand for co-delivery of multiple therapeutic agents of different 
structures and physicochemical properties to combat drug-resistance and improve 
cancer therapy, as well as for simultaneous therapy and diagnostics. Therefore, elegant 
chemistry approaches are needed to synthesize biodegradable and biocompatible 
polymers with defined molecular structure, well-controlled molecular weight and 
functionalities in both hydrophobic and hydrophilic blocks so that micelles with 
narrow size distribution can be fabricated with increased drug loading capacity via 
non-covalent interaction and a capability of active targeting and binding of 
macromolecular therapeutics. Control over geometry of polymer micelles can also 
provide many exciting opportunities for enhancing cellular uptake and intracellular 


























Figure 2.4 Number of yearly publications on polymer micelles for delivery of therapeutics from 
PubMed Search with “Polymeric Micelle” and “Delivery” as the keywords 
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III. DESIGN OF SELF-ASSEMBLED AMPHIPHILIC PEPTIDE FOR IN 
VITRO GENE CARRIER 
 
3.1. Introduction 
The most recent progress in the areas of molecular biology, biomedicine and 
biomaterial research has made non-viral gene delivery into animal cells emerged as an 
important research field. Its high potential application in the commercial area of large-
scale recombinant antibody production and its significant impact in the improvement 
of therapeutic approach for many hereditary human diseases attract many researchers 
in this field to find ideal solutions to deliver foreign genes into various animal cells 
[38]. In addition, the study of gene functions and regulations in certain cells also 
provide strong motivation for material scientists to develop biocompatible materials to 
carry genes into various cells without affecting their inherent signaling pathways. 
Various cationic polymers [98, 121, 131] and dendrimers [132] have been reported as 
non-viral vectors, and some of them are efficient in inducing high gene transfection in 
vitro. However, many of them are cytotoxic to the host cells. In attempting to address 
this issue, cationic oligopeptides have also been proposed as non-viral gene vectors 
[133-136].  
In a typical non-viral gene delivery vector, a cationic-based material is generally 
used to condense foreign DNA into a vector/DNA complex. However, as the 
mechanism governing the gene delivery system consists of multiple steps [38], the 
success of non-viral gene delivery vector does not only depend on its ability to 
condense DNA into small particles, but also depends on its capability to escape the 
endosome/lysosome upon endocytosis of the vector/DNA complex for intracellular 
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delivery of DNA. Vectors are often designed to exhibit buffering-capability to absorb 
protons in the acidic endosomal/lysosomal environment to induce endolysosomal 
escape, a mechanism which is widely known as ‘proton-sponge” effect [13, 137]. 
Histidine, which has an imidazole group with a pKa of 6, can thus absorb protons in 
the endosomal environment (pH 5-6.5). Introduction of histidine residues into 
oligopeptides was reported to promote gene transfection through the enhancement of 
this “proton-sponge” mechanism [138-140]. However, in most oligopeptides reported 
in the literature, the number of cationic charges is limited in each molecule. Therefore, 
DNA binding ability of oligopeptides is relatively weak, resulting in larger size of 
oligopeptide/DNA complexes and/or lower gene transfection efficiency as compared to 
the cationic polymer counterparts [134, 135]. 
Recently, Wang et al reported the use of cationic nanoparticles self-assembled 
from an amphiphilic copolymer as a gene carrier. These nanoparticles induced high 
gene expression efficiency in various cancer cell lines and primary human cells 
because of high cationic charge density on the surfaces and stable core/shell structure 
[116, 117]. However, like other cationic polymers, they caused certain cytotoxicity. In 
this study, cationic and amphiphilic oligopeptides, which were able to self-assemble 
into core/shell nanoparticles, were designed and tailored to function as a gene vector. It 
was expected that the formation of the micellar nanoparticles would increase the local 
cationic charge density in the solution, allowing for better complexation of DNA. In 
addition, the oligopeptides made from naturally-occurring amino acids would be 
biodegradable and biocompatible. The construct of the proposed peptide amphiphiles 
contained three blocks of amino acid residues, namely 12 L-alanine, 5 L-histidine and 
10 or 15 L-lysine residues (AK27 or AK32). The rationale behind the selection of each 
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amino acid was firstly to provide driving force for micelle formation by hydrophobic 
interaction among the alanine residues; secondly to condense DNA with the protonated 
amine group in the side chain of the lysine residues; and finally to create buffering 
capacity through protonation of the imidazole groups in the side chains of the 
remaining histidine residues upon endocytosis. The formation of the micellar 
nanoparticles from AK27 and AK32 was studied with critical micelle concentration 
determination and electron microscopy. Luciferase-encoding plasmid was used as a 
reporter gene. The AK27/DNA and AK32/DNA complexes were characterized by 
particle size and zeta potential in comparison with the DNA complexes formed from 
the peptide without the hydrophobic block (H5K10). Luciferase gene expression levels 
induced by the complexes were studied in HEK293 human embryonic kidney, HepG2 
human liver carcinoma and 4T1 mouse breast cancer cell lines. In addition, the 
cytotoxicity of the pure peptides and peptide/DNA complexes was also tested with the 
same cell lines. 
 
3.2. Materials and Methods 
3.2.1. Materials  
Acetic acid, sodium acetate, sodium chloride, sodium dihydrogen phosphate, 
disodium hydrogen phosphate, polyethyleneimine (PEI, branched, Mw 25kDa), phenol, 
agarose, ethidium bromide, thiazole orange and 3-[4,5-dimethylthiazolyl-2]-2,5-
diphenyl tetrazolium bromide (MTT) were all purchased from Sigma-Aldrich (France) 
and used as received. PBS, tris-boric acid-EDTA (TBE) and Tris EDTA (TE) buffers 
were all purchased from 1st BASE (Malaysia) and diluted to the intended concentration 
before use. RQ1 RNase-free DNase I enzyme, reporter lysis buffer and luciferin 
substrate were purchased from Promega (U.S.A.), and DNA ladder was purchased 
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from Fermentas (Canada). DMEM and RPMI 1640 growth media, fetal bovine serum 
(FBS), penicillin and streptomycin were all purchased from Invitrogen Corporation 
(U.S.A.). Plasmid DNA encoding the 6.4kb firefly luciferase (pCMV-luciferase 
VR1255C) driven by cytomegalovirus (CMV) promoter was kindly provided by Car 
Wheeler, Vical (U.S.A.), which was amplified in E. coli DH5a and purified with 
Endofree Giga plasmid purification kit supplied by Qiagen (Dutch). HEK293, HepG2, 
and 4T1 cell lines were all obtained from ATCC (U.S.A.) and grown with the 
recommended conditions according to the supplier. The AK27, AK32 and KH15 
peptides were designed by us and synthesized in GL Biochem (Shanghai) Ltd (P.R. 
China) at more than 95% purity. 
 
3.2.2. Methods 
3.2.2.1. CMC estimation 
A series of peptide solutions containing 0.6 μM pyrene were prepared at various 
concentrations (0.0625 to 20 mg/mL) in PBS buffer (pH 7.4) and incubated at 37oC 
overnight under gentle shaking. When excited at 337 nm, the electrons in the pyrene 
molecules absorb energy, and in turn, emit photons at wavelengths between 350-450 
nm, as indicated by five emission peaks in the fluorescence spectrum of pyrene [141]. 
At the concentration of amphiphile above its CMC, the amphiphile formed micellar 
nanoparticles having a hydrophobic core and a hydrophilic shell. The pyrene 
molecules were thus solubilized into the core of the nanoparticles, giving higher 
intensity of the third peak in the emission spectrum. Therefore, monitoring the 
intensity of the third peak (I3) of pyrene’s emission spectra, usually normalized to the 
first peak’s intensity (I1), provides a means to estimate the transition concentration (i.e. 
CMC) of the amphiphile aggregation. 
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3.2.2.2. Preparation of peptide/DNA or PEI/DNA complexes. 
The peptides were dissolved in 10 mM phosphate buffer (pH 6.5 or 7.1) or 20 
mM sodium acetate buffer (pH 5), and PEI solution was prepared in water of HPLC 
grade. The complexes were formed by directly mixing equal volume of peptide/PEI 
and plasmid DNA solutions to achieve the intended N/P ratio, which measured the 
relative molar content of nitrogen atoms (N) in each peptide molecule to that of the 
phosphate groups (P) in each DNA molecule. The phosphate content of the DNA 
molecule was estimated based on the standardized 3 µg DNA/nmole phosphate group 
rule of thumb as described in the literature [142]. Nitrogen content of the peptide 
molecule was estimated based on the number of lysine residues in each peptide 
molecule. To allow for complete electrostatic interaction between peptide/PEI and 
DNA molecules, the solution was equilibrated at room temperature for 30 minutes 
upon mixing before being used for further studies. 
 
3.2.2.3. Scanning Electron Microscopy (SEM) and Transmission Electron 
Microscopy (TEM) 
Morphology of micellar nanoparticles formed from AK27 and AK32 were 
observed using a field emission scanning electron microscope (JEOL JSM-7400F, 
Japan) operated at 25.0 kV accelerating voltage under the transmission electron mode. 
Both peptides were dissolved in de-ionised water at a concentration above their CMC 
(i.e. 3mg/mL), and equilibrated for at least 15 minutes at room temperature to allow for 
the self-assembly of the amphiphilic molecules. Several droplets of each sample were 
then added onto copper grid, where the particles were air-dried and imaged. 
AK27/DNA and AK32/DNA complexes were formed at N/P 40 in 10 mM phosphate 
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buffer (pH 6.5) according to the complex formation protocol described earlier. A small 
amount of complex solution (~5mL) was then dropped onto a TEM copper grid, and 
dried before TEM analysis (JEOL-2010, Japan, operated with an electron kinetic 
energy of 200 k eV). 
 
3.2.2.4. DNA retardation assay 
Various formulations of AK27/DNA, AK32/DNA and KH15/DNA complexes 
were prepared with N/P ratio ranging from 1 to 10. Post-equilibration, the complexes 
were electrophoresed on 1% agarose gel (stained with 4 mL of 0.5 μg/mL ethidium 
bromide per 50 mL of agarose solution) in 0.5×TBE buffer at 80 mV for 60 minutes. 
The gel was then analysed on a UV illuminator (Chemi Genius, Evolve, Singapore) to 
show the position of the complexed DNA relative to that of naked DNA. 
 
3.2.2.5. Thiazole orange exclusion assay 
Peptide/DNA complexes were formed in 10 mM phosphate buffer (pH 6.5 or 
7.1) according to the complex formation procedures described earlier. Aliquots of 
these complex solutions (50mL) were then diluted with PBS buffer (pH 7.4) containing 
0.38 mC thiazole orange. Fluorescence of the solutions was measured on a fluorimeter 
(Perkin Elmer, UK) by exciting the solutions at 500 nm, while monitoring the emission 
spectrum at 530 nm. The relative fluorescence intensity was reported as the 
fluorescence intensity of the peptide/DNA complex samples normalized to that of the 
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3.2.2.6. DNA degradation assay 
In order to verify the ability of the peptides to protect DNA from enzymatic 
degradation, complexes formed using AK27, AK32 and KH15 peptides at three 
different N/P ratios (N/P 1, 20, and 40) were incubated with equal volume (100mL) of 
DNase I enzyme for different reaction times (0, 10, 30, 60 minutes) at 37ºC. Post-
incubation, the reaction was stopped by adding stop solution into the reaction mixture, 
which was further incubated at 60ºC for 10 minutes. DNA was then extracted with a 
mixture of phenol and chloroform solution (50:50 in volume, 400 mL). The extracted 
DNA was then precipitated with ice-cold absolute ethanol (700 mL), air-dried and re-
dissolved in TE buffer (10 mL) for analysis. The DNA integrity was examined by 
assaying the extracted DNA solutions through 1% agarose gel at 80mV for 35 minutes. 
 
3.2.2.7. Particle size and zeta potential measurements 
The particle size and zeta potential of the peptide or PEI/DNA complexes were 
measured by dynamic light scattering (Brookhaven Instrument Corp., Holtsville, NY, 
U.S.A.) and Zetasizer (Malvern Instrument Ltd., Worchestershire, UK), respectively. 
Briefly, AK27/DNA, AK32/DNA and KH15/DNA complexes were formed in 10 mM 
phosphate buffer (pH 6.5) at room temperature at various N/P ratios (i.e. 1, 10, 20, 30, 
40 and 50). PEI/DNA complexes were prepared in water of HPLC grade at the optimal 
N/P ratio (i.e. 10). All the particle size measurements were performed with a He-Ne 
laser beam at 658 nm and a scattering angle of 90°. The particle size measurement 
was repeated for 5 runs for each sample, and the data was reported as the average of 
the effective mean diameters of 5 runs. The zeta potential measurement was repeated 
for 3 runs per sample, and the data was calculated automatically using the software 
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from the electrophoretic mobility based on the Smoluchowski’s formula. Before the 
actual measurement, the complex solutions were subjected to 10 times dilution with 
PBS (pH 7.4) to mimic the conditions employed for the in vitro gene expression 
experiments. 
 
3.2.2.8. Cell culture 
Both HEK293 and HepG2 cell lines were cultured in DMEM medium 
supplemented with 10% FBS, 100 µg/mL penicillin and 100 µg/mL streptomycin, and 
incubated at 37ºC, 5% carbon dioxide. 4T1 cell line was also cultured under the same 
conditions, but in RPMI 1640 growth medium supplemented with 10 mM HEPES. 
 
3.2.2.9. Cytotoxicity test 
The cytotoxicity of AK27, AK32, KH15, PEI, AK27/pDNA, AK32/pDNA and 
KH15/pDNA complexes was evaluated against HEK293, HepG2 and 4T1 cell lines 
using the standard MTT assay protocol. Briefly, cells were seeded onto 96-well plates 
at 10,000, 8,000 and 6,000 cells/well seeding density for HEK293, HepG2 and 4T1 
cell lines, respectively, and incubated for one day. Peptide/DNA complexes at N/P 
ratios of 1, 10, 20, 30, 35, 40, 45 and 50 were prepared in 10 mM phosphate buffer (pH 
6.5) as described earlier. Blank peptide solutions were prepared by mixing an equal 
volume of peptide solution with buffer solution (instead of DNA solution for complex 
formation) to achieve same peptide concentration as DNA complexes. The cells were 
then incubated with the sample-containing growth medium (20 mL of peptide, PEI or 
complex solution in 200 mL of fresh growth medium per well). After incubation of 4 
hours, the cells were washed once with PBS buffer, and incubated with the fresh 
medium for further 68 hours. The growth media were then replaced with the fresh ones 
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(100mL) and MTT in PBS (10 mL, 5mg/mL), and the cells were incubated for 4 hours. 
The media were removed and 150 mL of DMSO was added into each well to dissolve 
the internalised purple formazan crystals. An aliquot of 100 mL was taken from each 
well and transferred to a fresh 96-well plate. The plates were then assayed at 550 nm 
and 690 nm. The relative cell viability was measured as {([Abs550]sample – 
[Abs690]sample)/ ([Abs550]control – [Abs690]control)} ´ 100%. Cytotoxicity test was repeated 
eight times. Data are expressed as mean ± standard deviations of six to eight replicates. 
Statistical analysis was performed using Student’s t-test. Differences were considered 
statistically significant with p < 0.05. 
 
3.2.2.10. In vitro gene expression 
The in vitro gene transfection of the peptide or PEI/DNA complexes was 
performed in HEK293, HepG2 and 4T1 cell lines. The cells were seeded onto 24-well 
plates at a density of 8×104, 8×104 and 5×104 cells/well respectively, and cultivated in 
0.5 mL of the respective growth medium. After 24 hours, the culture medium was 
replaced with fresh growth medium (supplemented with 10% FBS), and complex 
solution (50 mL) containing 2.5 µg DNA was added to each well. After 4 hours of 
incubation, the culture media were replaced with the fresh ones. The culture media 
were removed after 68 hours, and the cells were washed with 0.5 mL of PBS. Reporter 
lysis buffer (0.2 mL) was then added to each well to lyse the cells. The cell suspension 
was subjected to two cycles of freezing (-80ºC, 30 minutes) and thawing, and then 
centrifuged at 14,000 rpm for 5 minutes. The supernatant of the cell lysate (20 µL) was 
mixed with 100 µL of luciferase substrate (Promega). The relative light units (RLU) 
were measured using a luminometer (Lumat LB9507, Berthold, Germany), and 
normalized to protein content measured using the BCA protein assay (Sigma). In all 
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these experiments, naked DNA-transfected cells were used as negative control. Gene 
transfection experiment was repeated for six times. Data are expressed as mean ± 
standard deviations of four to six replicates. Statistical analysis was performed using 
Student’s t-test. Differences were considered statistically significant with p < 0.05. 
 
3.3. Results and Discussions 
3.3.1. Micelle formation 
The formation of the micelles (i.e. core/shell nanoparticles) from the amphiphilic 
peptides was firstly evidenced by the existence of their critical micelle concentrations 
(CMC). The CMC values of amphiphilic peptides were estimated by fluorescence 
spectroscopy using pyrene as a probe. A higher peak ratio of I3/I1 obtained from the 
emission spectra of pyrene was observed when pyrene was located in a more 
hydrophobic environment [141]. As shown in Figure 3.1, the I3/I1 ratio of pyrene 
against the logarithm of peptide concentration gave an inflection when the amphiphile 






Figure 3.1 Plot of intensity ratio of I3 to I1 as a function of logarithm of AK27 and AK32 concentration 
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The inflection point could be estimated through the intersection of best-fit line passing 
I3/I1 data-points at lower concentrations with that passing the data-points at high 
concentrations. For the two peptides, an estimate of the CMC in phosphate-buffered 
saline (PBS, pH 7.4) was approximately 0.9 and 1.1 mg/mL for AK27 and AK32, 
respectively, indicating that the AK27 or AK32 micelles were formed at 
concentrations above the CMC values. Compared to AK27, AK32 with a longer 
hydrophilic lysine block had a slightly higher CMC value owing to the increased 
repulsive forces experienced by the longer hydrophilic lysine groups, which made 











Figure 3.2 SEM images of micellar particles self-assembled from AK27 (a) and AK32 (b); TEM images 
of AK27/DNA (c) and AK32/DNA (d) complexes formed at N/P ratio of 40. Scale bar: 100 nm for (a) 
and (b); 0.5 µm for (c) and (d). 
 
The formation of the micelles was further confirmed with the scanning electron 
microscopic (SEM, operated under transmission mode) images of the peptides (Figure 
(a) (b) 
(c) (d) 
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3.2a and b). The micelles were cubic in nature, and the reason for the formation of 
cubic structure is still unknown. The size of AK32 micelles was observed to be smaller 
than that of AK27 micelles because of the increased repulsion between the longer 
hydrophilic lysine blocks, which led to the reduced number of oligopeptide molecules 
in each micelle. 
 
3.3.2. DNA binding ability of peptide 
The DNA binding ability of the peptides was evaluated by gel retardation assays. As 
shown in Figure 3.3, the peptides efficiently bound DNA even at low N/P ratios. The 
complete retardation of DNA was achieved at N/P ratio of 2 for both AK27 and AK32 
peptides at equivalent concentrations below their CMC values. A comparable DNA 
retardation pattern was also observed with the control peptide, H5K10 (KH15), i.e., 
complete retardation of DNA also occurred at N/P ratio of 2 for KH15. Although DNA 
was not well condensed by AK27 and AK32 at low N/P ratios and KH15 as large 
particles were formed (Table 3.1), the binding of the peptides was sufficient to prevent 
DNA from travelling across the gel. 
The complexation of DNA with the peptides was further analysed with thiazole 
orange exclusion assays. It was reported that thiazole orange could intercalate with 
DNA; the benzothiazole group of the thiazole orange molecule is intercalated between 
two pyrimidine bases, whereas the quinolinium ring is inserted between two purine 
bases [144, 145]. Upon intercalation, both the benzothiazole and quinolinium rings are 
locked in a plane, hindering any rotational movement around the interconnecting 
bonds, and hence inhibiting any relaxations upon excitation of intercalated thiazole 
orange molecules. 
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Figure 3.3 Electrophoretic mobility of DNA in peptide/DNA complexes. (a) AK27/DNA, (b) 
AK32/DNA and (c) KH15/DNA. Lane 1, 2, 3, 4, 5, 6, 7, and 8 are DNA ladder, naked DNA, complexes 
at N/P ratio of 1, 2, 3, 4, 5 and 10, respectively. 
 
This dye would therefore give out fluorescent signal at 530 nm upon excitation at 500 
nm [136]. Upon condensation with peptides, thiazole orange is excluded from 
intercalating DNA molecules, resulting in quenching of the fluorescence intensity of 
thiazole orange. As shown in Figure 3.4, thizole orange fluorescence decreased with 
increasing peptide content in the complexes. For both AK27 and AK32 peptides, the 
maximum reduction in fluorescence intensity was observed at N/P ratio of 2, while for 
KH15, it occurred at N/P ratio of 3. This observation was in agreement with the gel 
electrophoresis assays (Figure 3.3), and at N/P ratio of 2 or 3 and above, the binding of 
DNA with the peptides efficiently excluded thiazole orange molecules. Slightly 
stronger DNA binding ability of AK27 and AK32 peptides was observed when 
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Figure 3.4 Thiazole orange exclusion from the peptide/DNA complexes. 
 
3.3.3. DNA degradation assay 
In the physiological environment, foreign DNA is subjected to enzymatic degradation 
by nucleases that existed both in the blood and in the cell cytoplasm. It is, therefore, 
necessary for the delivery vector to be able to condense such foreign DNA through 
electrostatic interactions and protect them from enzymatic degradation. The 
degradation of DNA in the peptide/DNA complexes was studied by exposing the 
complexes formed at N/P ratio of 1, 20 or 40 to DNase I enzyme. As a control, the 
naked DNA was treated with DNase enzyme for 10 minutes under the same conditions 
as the treatment for the complexes. For both AK27 and AK32 peptides, N/P ratios of 1 
and 20 were achieved at peptide concentrations below their CMC, while N/P ratio of 
































Self-Assembled Oligopeptide Nanostructures for      Chapter 3 
















Figure 3.5. Enzymatic degradation of DNA. (a) naked DNA; (b) DNA extracted from AK27/DNA 
complexes; (c) DNA extracted from AK32/DNA complexes; (d) DNA extracted from KH15/DNA 
complexes. (a) Lane 1, 2 and 3: DNA ladder, naked DNA and naked DNA treated with DNase I for 10 
min; (b), (c) and (d) Lane 1, 2-5, 6-9 and 10-13 are naked DNA and peptide/DNA complexes at N/P 
ratio of 1, 20 and 40 with exposure time of 0, 10, 30 and 60 min respectively. 
 
As illustrated in Figure 3.5a, complete degradation of naked DNA was 
observed after 10 minutes incubation with DNase I enzyme. Comparing with the bands 
of naked DNA (Lane 1 in Figure 3.5b-d), both high and low mobility bands were still 
preserved when DNA was complexed with the peptide molecules (Lanes 2-13 in 
Figure 3.4b-d), suggesting the ability of peptide molecules to condense DNA and 
protect DNA from nuclease degradation. Some fragments of DNA were observed 
(b) (a) (b) 
N/P 1 (0, 10, 30, 60min) N/P 20 (0, 10, 30, 60min) N/P 40 (0, 10, 30, 60min) 
1 2 3 4 5 6 13 12 11 10 7 8 9 
 
N/P 1 (0, 10, 30, 60min) N/P 20 (0, 10, 30, 60min) N/P 40 (0, 10, 30, 60min) 
(c) 
 




A N/P = 1 N/P = 20 N/P = 40 
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when it was complexed with both AK27 and AK32 at N/P ratio of 1, which was 
implied by the presence of the continuous DNA bands in Figure 3.5b and c (Lanes 3-
5). Such DNA fragmentation was greatly reduced and completely eliminated when N/P 
ratio was increased to 20 and 40, as shown in the same figure (Lanes 6-13). However, 
at the same high N/P ratios, partial degradation of DNA could be observed for AK27 
peptide, as shown by the presence of middle mobility band after the DNA complexes 
were exposed to DNase I enzyme for 30 and 60 minutes. In contrast, fragmentation of 
DNA was hardly observed in AK32/DNA complexes even after long exposure to 
DNase I enzyme for 60 minutes owing to the increase in cationic charge density in 
AK32 peptide. In addition, enzymatic exposure of KH15/DNA complexes showed that 
there was significant degradation, which was indicated by both the DNA fragments 
and additional middle mobility band even at N/P ratio of 40 (Figure 3.5d). This finding 
suggests that the presence of the hydrophobic block in both AK27 and AK32 peptides 
plays an important role in protecting DNA from enzymatic degradation, plausibly by 
increasing local concentration of cationic charge in the form of micellar peptide 
nanoparticles and thus promoting DNA binding. 
 
3.3.4. Particle size, zeta potentials, and morphology analysis 
As listed in Table 3.1, there was a general decreasing trend in the particle size 
and an increasing trend in the zeta potential of the peptide/DNA complexes as the N/P 
ratio was increased. Although blank AK27 and AK32 peptides formed large micellar 
particles, peptide/DNA complexes especially at high N/P ratios were much smaller. At 
N/P ratios of 30 and above, the concentrations of AK27 and AK32 employed were 
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above their CMC values, leading to the formation of micelles before being complexed 
with DNA.  
Table 3.1 Effective mean diameter and zeta potential of AK27/DNA, AK32/DNA, KH15/DNA and 
PEI/DNA complexes 
Effective mean diameter [nm] Zeta potential [mV] Vector N/P Ratio 
Average Standard 
deviation 
PDI Average Standard 
deviation 
Blank Peptide 854 65 0.31 +18.6 1.4 
1 630 85 0.23 -31.5 1.1 
10 529 34 0.19 +4.7 0.5 
20 469 82 0.01 +7.1 0.5 
30 481 63 0.12 +7.3 0.4 
40 442 41 0.22 +7.8 1.1 
AK27 
50 507 57 0.14 5.4 0.3 
Blank Peptide 787 34 0.32 +20.1 0.4 
1 444 11 0.14 -30.9 1.8 
10 382 44 0.15 +11.9 1.8 
20 355 57 0.17 +10.0 0.1 
30 332 25 0.13 +15.4 1.5 
40 350 30 0.12 +18.2 0. 5 
AK32 
50 561 59 0.16 +12.4 1.2 
Blank Peptide 671 48 0.28 +12.7 1.0 
1 340 15 0.15 -30.3 1.1 
10 3480 334 0.23 -0.1 0.0 
20 4949 300 0.37 -0.3 0.6 
30 3147 200 0.25 +0.1 0.1 
40 3852 855 0.34 +2.3 0.3 
KH15 
50 3146 831 0.26 +5.4 0.2 
PEI 10 187 8 0.14 +20.5 3.1 
 
The formation of micelles might increase the local concentration of positive charge in 
the solution, promoting efficient DNA binding. After being complexed with DNA, the 
peptide particles might be rearranged together with DNA molecules to form smaller 
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particles. The smallest particle size was around 442+41 nm for AK27/DNA complexes 
at N/P ratio of 40, and 332+25 nm for AK32/DNA complexes at N/P ratio of 30. In 
sharp contrast, the control peptide KH15 provided poor DNA binding capacity, leading 
to the formation of micron-sized particles. 
Similar to particle size, the surface charge of the complexes is also one of the 
important factors influencing the efficiency of gene expression. Ideally, net positive 
charge after complexation is preferred to enhance the cellular uptake of the complexes, 
owing to the interaction between the negatively-charged cell membrane and the 
positively-charged complexes. Therefore, the higher the net positive charges of the 
complexes, the more easily the complexes would be taken up by the cells. However, if 
the net positive charge of the complexes is too high, it may make the cell membrane 
more susceptible to being disrupted, causing cellular toxicity. For both AK27 and 
AK32 peptides, the highest zeta potential was achieved at N/P ratio of 40, being 
approximately 7.8+1.1 and 18.2+0.5 mV, respectively. Compared to AK27, AK32 
with a longer protonable lysine block provided higher positive charge density on the 
surface of the blank peptide particles, leading to an increased zeta potential of the 
peptide/DNA complexes. Furthermore, the complexes formed from the control HK15 
peptide had zeta potential values close to the neutral charge even at high N/P ratios, 
leading to the aggregation of complexes. This observation strongly supports our 
hypothesis that the pre-formation of micelles increased local cationic charge density 
and promoted DNA condensation.  
The transmission electron microscopic (TEM) images of AK27 and 
AK32/DNA complexes formed at N/P ratio of 40 are shown in Figure 3.2c and d. After 
being complexed with DNA, the cubic shape of the peptide particles was conserved. 
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The sizes of blank peptide particles and peptide/DNA complexes shown in Figure 3.2 
were smaller than those analyzed by dynamic light scattering because the particles 
shrank during the drying process prior to TEM and SEM analyses. 
 
3.3.5. Cytotoxicity of peptide and peptide/DNA complex 
Ideally, vector materials should not induce cytotoxic effects. The cytotoxicity of 
peptides and peptide/DNA complexes was evaluated against HEK293, HepG2 and 4T1 
cell lines. As shown in Figure 3.6, all peptides and peptide/DNA complexes had low 
cytotoxicity to the cells even at high concentrations, at which micelles were formed, 
giving cell viability of about 80% or higher. This was better than PEI at a 
concentration for its optimal N/P ratio (i.e. 10), at which PEI induced high gene 
expression yet provided more than 50% cell viability. It can also be observed that an 
increased length of the protonable lysine block and the presence of the hydrophobic 
block did not significantly increase the cytotoxicity of the peptides. Furthermore, 
complexation with DNA decreased the cytotoxicity of the peptides especially against 
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Figure 3.6 Cell viability of HEK293 (     ), HepG2 (     ) and 4T1 (     ) cell lines after incubation with 
AK27 (a), AK27/DNA (b), AK32 (c), AK32/DNA (d), KH15 (e) and KH15/DNA (f) peptides and 
complexes at different concentrations in comparison with PEI at N/P ratio of 10. Error bars represent 
standard deviation of 8 replicates. Peptide concentrations: AK27-40, 390, 770, 1160, 1350, 1740 and 
1930 µg/mL; AK32-30, 330, 650, 980, 1140, 1300, 1470 and 1630 µg/mL; HK15-30, 270, 540, 810, 
950, 1080, 1220 and 1350 µg/mL. 
 
3.3.6. Complexation pH-dependent in vitro gene expression 
The pKa of the imidazole side group in histidine is known to lie around 6; and 
therefore, in aqueous solutions with pH above this value, this side group is 
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residue is around 10, in aqueous solutions with pH below this pKa, lysine is 
protonated, causing it to carry positive charges. Therefore, there may be an optimum 
complexation pH for gene expression. Figure 3.7 summarizes the luciferase expression 









Figure 3.7 Effect of complexation pH on luciferase expression of AK27/DNA complexes in HEK293 
cell line. Error bars represent standard deviation of 6 replicates. Peptide concentrations: 40, 390, 770, 
1160, 1350, 1740 and 1930 µg/mL. 
 
The lowest gene expression efficiency was obtained when the complexation 
was performed at pH 5. This was expected since at pH 5, about 91% histidine groups 
and 100% lysine residues were protonated, leaving fewer protonable histidine groups 
to facilitate endosomal escape through the ‘proton-sponge’ effect upon endocytosis. 
When complexation pH was changed to be above the pKa value of histidine, i.e. at pH 
6.5 and 7.1, it was shown that the gene expression efficiency was higher than that 
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capacity of histidine at pH lower than pKa of histidine (i.e. 6). Furthermore, the 
maximum luciferase expression level induced by the DNA complexes formed at pH 
6.5 was significantly higher than that mediated by the DNA complexes fabricated at 
pH 7.1. At both pH 6.5 and 7.1, almost 100% lysine groups were protonated. However, 
at the lower pH, more histidine groups were protonated (24% vs. 6%), which might 
lead to stronger DNA binding and thus higher gene transfection efficiency. This 
complexation pH-dependent gene expression efficiency exhibited the equal importance 
of both buffering capacity and DNA binding ability of the vector. 
 
3.3.7. Luciferase expression in various cell lines 
The luciferase expression efficiency induced by AK27 and AK32 peptides was 
investigated in HEK293, HepG2 and 4T1 cell lines at different N/P ratios in 
comparison with KH15 and PEI. The DNA complexes were formed at pH 6.5 for the 
peptides. As shown in Figure 3.8, the luciferase expression efficiency was dependent 
on cell type, N/P ratio and peptide composition. The gene expression level induced by 
peptides in all the three cell lines increased with increasing N/P ratio, and among the 
three peptides, AK32 yielded the highest gene expression levels. For instance, in 
HEK293 cell line, the highest gene expression level achieved by AK32 at N/P ratio of 
35-45 was about 15 and 5 times higher than those yielded by KH15 at N/P ratio of 40-
45 and AK27 at N/P ratio of 45 respectively. Similar phenomena were also observed in 
HepG2 and 4T1 cell lines. At N/P ratios of 30 and above, AK27 and AK32 peptides 
formed micelles before being complexed with DNA, leading to stronger DNA binding 
ability when compared to KH15 (Figure 3.4). On the other hand, compared to 
KH15/DNA complexes, the AK27/DNA or AK32/DNA complexes had positively 
charged surfaces and smaller particle size (Table 3.1), which might promote cellular 
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uptake [146]. All these factors are possible reasons for higher gene expression 
efficiency induced by AK27/DNA and AK32/DNA complexes. AK32 with a longer 
length of lysine block achieved greater gene expression efficiency when compared to 
AK27 possibly because the higher positive charge density and the smaller size of 
AK32/DNA complexes (Table 3.1) might induce greater cellular uptake [146]. In 
addition, it was also observed from Figure 3.8 that the highest luciferase expression 
level induced by AK32 was comparable to that provided by PEI (especially in HepG2 
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Figure 3.8 Luciferase expression levels induced by KH15/DNA (a), AK27/DNA (b) and AK32/DNA (c) 
complexes in HEK293 (    ), HepG2 (     ), and 4T1 (     ) cell lines in comparison with PEI at N/P ratio of 
10. Error bars represent standard deviation of 6 replicates. Peptide concentrations: HK15-30, 270, 540, 
810, 950, 1080, 1220 and 1350 µg/mL; AK27-40, 390, 770, 1160, 1350, 1740 and 1930 µg/mL; AK32-
30, 330, 650, 980, 1140, 1300, 1470 and 1630 µg/mL. 
 
3.4. Conclusions 
In this study, it was proven that the amphiphilic AK27 and AK32 peptides were 
able to self-assemble into cationic and micellar nanoparticles in aqueous solutions. The 
formation of the nanoparticles yielded a greater local concentration of positive charges, 
providing a stronger DNA binding ability, and thus efficiently preventing DNA from 
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were positively charged, they had little cytotoxicity against the cell lines tested in this 
study, which was much lower than that induced by PEI. On the other hand, the 
peptide/DNA complexes induced high gene expression levels in vitro. In particular, the 
gene expression levels mediated by AK32 nanoparticles were comparable to that 
obtained by PEI especially in HepG2 and 4T1 cell lines. Therefore, the cationic, 
biocompatible and biodegradable peptide nanoparticles may provide a promising 
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IV. DESIGN AND EVALUATION OF PEPTIDE AMPHIPHILES WITH 
DIFFERENT HYDROPHOBIC BLOCKS FOR SIMULTANEOUS 
DELIVERY OF DRUGS AND GENES 
 
4.1. Introduction 
Self-assembled nanoparticles in the field of cancer therapy have emerged as an 
important class of technology with highly promising applications [147-151]. In 
particular, cancer gene therapy has increased much attention among bioengineers and 
material scientists in the past decades, especially after the discoveries of the underlying 
defective cancer-related genes at the cellular and molecular levels. Not only that the 
application of such technology is important in combating cancer, the fundamental 
phenomena on the self-assembled nanoparticles is equally important, so as to provide 
guidelines for designing a better particulate delivery system in a more controlled 
manner. This is particularly true since self-assembly is a thermodynamically-controlled 
process, rendering molecular design strategy as a key important point in achieving the 
desired final equilibrium properties of the nanostructured particles.  
In the previous chapter, a thorough study on the design and application of 
cationic oligopeptide nanostructure self-assembly for gene delivery was reported. The 
study presented promising results, in terms of its capability to induce a decent 
transgene expression at a relatively lower cytotoxicity compared to the golden cationic 
polymer benchmark [152]. However, there is still a drawback in that peptide design, 
especially in its high micellization concentration property (CMC value), rendering it 
less desirable for in vivo applications. Moreover, the size of the nanoparticle 
assemblies formed by the peptide sequence was found to be relatively large for in vivo 
application. In this chapter, investigation on the effect of hydrophobicity of the 
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hydrophobic tail of the previously designed tri-block peptide amphiphile is revisited. 
The motivation behind this study was to understand the structure-property relationship 
between the hydrophobic tails of the oligopeptide amphiphile on its micellization 
capability, with an eventual goal of achieving a more stable self-assembled 
nanoparticulate system with a low enough critical micellization concentration (CMC) 
to allow drug incorporation into the core of the nanoparticles. In addition, it has also 
been reported in several studies that simultaneous delivery of anticancer drugs and 
genes provide synergistic effect resulting in an increased transgene expression in vitro 
[116, 153]. These in turn provide an even stronger motivation for the “search” of a 
simultaneous delivery vehicle with less cytotoxic material building blocks.  
In this study, modification of the hydrophobic block of the tri-block peptide, 
consisting 15 lysine, 5 histidine, and 12 alanine residues was performed. It was 
performed systematically by replacing the alanine residue in the hydrophobic block 
with a more hydrophobic natural amino acid according to the rule of (AmX)n, for the 
hydrophobic block content, with A: Alanine, X: other more hydrophobic amino acids, 
while keeping the total number of amino acid residues in this block to be constant at 12 
residues. As such, the maximum replacement of alanine that could be done was 6, i.e., 
when m=1, and n=6. The choice of amino acids to replace the original alanine residue 
is also not as complicated, as there are only limited numbers of natural hydrophobic 
amino acids. Based on the hydrophaty index (HI) of amino acids defined by Kyte and 
Doolittle, which measures degree of hydrophobicity of an amino acid, alanine is scaled 
at 1.8. Since the more positive the HI scale is, the more hydrophobic the amino acid is; 
an amino acid with larger HI scale will be selected for this study. A few other 
hydrophobic amino acid on the HI scales larger than alanine with relatively simpler 
solid phase synthetic chemistry protocol are phenylalanine (F, HI=2.8), leucine (L, 
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HI=3.8), and isoleucine (I, HI=4.5). Based on this HI scale, as well as the presence of 
aromatic side chain beneficial in providing p-p interactions, phenylalanine was chosen 
to systematically replace alanine residues in this study. In addition, to provide a 
comparison on the effect of the p-p interaction on drug entrapment capability, the 
maximum modification with phenylalanine, i.e., (AF)6, was further modified with 
leucine to become (AL)6. It is important to note that both the hydrophilic segment and 
histidine block were kept unaltered since these blocks are responsible for gene binding 
and endosomal escape purposes. Since gene delivery mediated by synthetic materials 
has been widely postulated to be dependent on DNA condensation capacity, 
endosomal escape, intracellular DNA release, nuclear targeting of DNA cargo [38], 
should there be any alteration in the transgene expression profile upon modification of 
the particles, the main variable would be due to the particulate system modification, 
which would not be confounded by any other intertwining factors affecting transgene 
expressions. The detailed sequence of the peptides designed and synthesized in this 
study is tabulated in Table 4.1. 











All the peptides listed in Table 4.1 were firstly synthesized via solid phase 
approach and characterized for their molecular weight. The effect of the degree of 
hydrophobicity as well as the side chain structure (aromatic/aliphatic) of the peptide on 
particle size, zeta potentials, CMC, and drug entrapment properties were characterized 
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thoroughly. Following that, peptides with the most suitable properties was further 
characterized in terms of its gene transfection capability with a reporter gene, 
cytotoxicity, and further used to perform simultaneous delivery of anticancer drugs 
(paclitaxel) and reporter gene to demonstrate the synergistic effect of such therapeutic 
system.  
 
4.2. Materials and Methods 
4.2.1. Materials 
Sodium chloride, sodium dihydrogen phosphate, disodium hydrogen 
phosphate, polyethylenimine (PEI, branched, Mw 25kDa), piperidine, N,N-
dimethylacetamide (DMAc), N-methyl morpholine (NMM), N-methyl pyrolidone 
(NMP), triethylamine (TEA), trifluoroavetic acid (TFA), tri-isopropyl silane (TIS), α-
cyano-4-hydroxycinnamic acid (CHCA) crystal, and 3-[4,5-dimethylthiazolyl-2]-2,5-
diphenyl tetrazolium bromide (MTT), and pyrene were all purchased from Sigma-
Aldrich and used as received. Endotoxin-free anticancer drugs, doxorubicin-HCl 
(DOX.HCl) was obtained from Boryung Pharmaceuticals (Korea) at purity of > 99%, 
while paclitaxel (PTX) was purchased from LC Labs (USA) at purity of >99.5%. Both 
drugs were used as it is. N,N-Dimethylformamide (DMF), dichloromethane (DCM), 
methyl-tert-butyl ether (MTBE), acetonitrile (ACN), were bought from Tee Hai 
Chemicals (Singapore) and used as reagents for peptide synthesis. 
Fluorenylmethoxycarbonyl (Fmoc)-protected amino acid monomers, such as Fmoc-
Ala-OH, Fmoc-His(Trt)-OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Phe-OH, and 
benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) were 
obtained from LC Sciences (U.S.A.). Rink Amide resin pre-loaded with L-lysine 
residue at substitution degree of 0.42 mmol/gram was also obtained from LC Sciences 
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(U.S.A.). Phosphate buffered saline (PBS, pH 7.4), was bought from 1st BASE 
(Malaysia) and diluted to the intended concentration before use. Reporter lysis buffer 
and luciferin substrate were purchased from Promega (U.S.A.). DMEM growth 
medium, fetal bovine serum (FBS), penicillin and streptomycin were all purchased 
from Invitrogen Corporation (U.S.A.). Plasmid DNA of 6.4 kb size encoding the 
firefly luciferase (pCMV-luciferase VR1255C) driven by cytomegalovirus (CMV) 
promoter was kindly provided by Car Wheeler, Vical (U.S.A.). It was amplified in E. 
coli DH5a strain after transformation of the bacteria, and purified with Endofree Giga 
plasmid purification kit supplied by Qiagen (Netherland). HepG2 cell line was 
obtained from ATCC (U.S.A.) and grown under the recommended conditions 
according to the supplier.  
 
4.2.2. Methods 
4.2.2.1. Peptide synthesis 
Various amphiphilic peptides, were designed and synthesized via the standard 
Fmoc chemistry protocols [154] with an automated Multipep Intavis AG (Cologne, 
Germany) peptide synthesizer. Table 4.1 summarizes the details on the peptide 
sequence synthesized in this study. Briefly, peptide chains were grown on Rink Amide 
MBHA resins, loaded with the first L-lysine amino acid residue. The synthesis was 
carried out at 50 mmol scale of the peptide substituted on the resin. Fmoc protecting 
groups were deprotected with 20% (v/v) piperidine during the synthesis. Coupling of 
amino acid monomers (5 molar eq) was either performed twice for the hydrophilic 
segments, or thrice for the hydrophobic segments, using PyBOP (5 molar eq) as the 
activator. At the end of the synthesis, the N-terminal was acetylated with acetic 
anhydride (5 molar eq) in the presence of N-methyl morpholine (10 molar eq). Upon 
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completion of the peptide synthesis, the peptides were cleaved from the resins by 
exposing the resins to cleavage cocktails (5mL) containing 95% trifluoroacetic acid, 
2.5% trisopropylsilane, and 2.5% de-ionized (DI) water (v/v) for 3 hours. Cleaved 
peptides were precipitated with ice-cold tert-butyl-methyl-ether, and centrifuged at 
4000 rpm for 20 minutes to recover peptides as precipitated solid. The peptide 
precipitates were vacuum-dried and re-dissolved in DMF and dialyzed against the 
same solvent with modified cellulose ester membrane with a molecular weight cut-off 
(MWCO) of 1000 Da (Spectra/Por 7, Spectrum Laboratories Inc.) to ensure removal of 
small molecular impurities. This dialysis was performed under gentle stirring for 4 
hours with the external DMF being changed hourly. After that, the dialysis bag 
containing peptide solution was dialyzed against running DI water overnight to ensure 
complete removal of DMF, followed by lyophilization. Lyophilized peptides were 
further purified with Agilent 1200 semi-preparative HPLC (Agilent, Santa Clara, 
U.S.A.) with Agilent Zorbax 300SB-C18 reverse phase column (10´250 mm). Mixture 
of ACN and water was used as the mobile phase, with a gradient slowly ramping from 
10% ACN to 40% ACN for the first 20 minutes, followed by quick ramping from 40% 
to 100% ACN for the next 10 minutes, and back to 10% ACN for the last 5 minutes of 
the run. The peptides were characterized by analytical reverse phase HPLC and matrix-
assisted laser desorption/ionization time-of-flight mass spectroscopy (MALDI-TOF 
MS, Model Autoflex II, Bruker Daltonics Inc., U.S.A.), where a-cyano-4-
hydroxycinnamic acid was used as matrix.  
 
4.2.2.2. CMC determination 
The CMC of the peptide amphiphiles was estimated by fluorescence 
microscopy using pyrene as a probe, according to the methods described in section 
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3.2.2.1 in the previous chapter [141]. However, since the peptide amphiphiles being 
studied in this chapter were more hydrophobic that those used in Chapter 3, the 
concentrations of the peptide solutions were varied at lower concentrations from 0 – 10 
mg/mL.  
 
4.2.2.3. Particle size and zeta potential analysis 
To investigate on the effect of hydrophobicity of the peptides on the particle 
size and zeta potentials of the nanostructures, various peptide solutions in PBS1X were 
prepared at concentration above its respective CMC. The particle size and zeta 
potential of the resulting self-assembled nanostructures was then measured with 
dynamic light scattering technique as described previously in Section 3.2.2.7. 
 
4.2.2.4. Drug encapsulation 
Doxorubicin was firstly loaded into peptide micelles through a membrane 
dialysis method as described in the literature [5]. Briefly, 10 mg of peptide was 
dissolved in 2 mL of DMAc, and 5 mg of DOX was dissolved in 2 mL of DMAc 
containing 3 molar equivalent of TEA. It was reported that at this molar ratio between 
DOX and TEA, most of the DOX.HCl molecules were neutralized to provide free and 
hydrophobic DOX molecules, which would lead to higher loading efficiency [155, 
156]. The peptide and DOX solutions were then mixed under mild vortexing. The 
peptide and DOX solution was dialyzed against DI water using modified cellulose 
ester membrane with MWCO of 1,000 Da (Spectra/Por 7, Spectrum Laboratories Inc.). 
The dialysis process employed would allow for the solvent exchange between DMAc 
and DI water to occur to induce the self-assembly of the nanoparticles, and at the same 
time remove the excess TEA and TEA.HCl molecules. The external aqueous solution 
Self-Assembled Oligopeptide Nanostructures for      Chapter 4 




was changed 4 times every 2 hours during the first day, and changed once on the 
second day of dialysis. After 48 hours of dialysis, the solution inside the dialysis bag 
was centrifuged (25oC, 2000 rpm) to remove precipitates. DOX-loaded micelles were 
then harvested by freeze-drying.  
To determine DOX loading level and encapsulation efficiency, a known 
amount of DOX-loaded micelles was dissolved in 1 mL of DMAc. The DOX 
concentration was estimated with a UV¯VIS spectrophotometer (Perkin Elmer, U.S.A.) 
at 485 nm. The drug content in the solution was calculated based on the standard curve 
obtained from DOX in DMAc. The loading level (LL) and encapsulation efficiency 













DOXofmassEE      (Eq. 4.2) 
 
For the peptide with the highest content of Phenylalanine, (AF)6, paclitaxel 
loading was also performed. Briefly 10 mg of peptide and 0.5mg of PTX was each 
dissolved in 2mL of DMF, pre-mixed, and dialysed against DI water. Similarly, the 
external DI water was changed every 2 hours for 4 times in the first day, followed by 
once in the second day. After 48 hours of dialysis, the precipitate was removed through 
a filtration process with 0.8 mm pore size filter. The drug encapsulated nanoparticles 
were recovered through lyophilisation process. Unlike DOX encapsulation, the loading 
and encapsulation efficiency of PTX was measured with HPLC. The lyophilized PTX-
loaded nanoparticle solids was firstly dissolved in 50% ACN/water mixture, and run 
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through a HPLC with Agilent Zorbax 300SB-C18 reverse phase column (10´250 mm) 
at a constant gradient of 50% ACN/Water as the mobile phase. PTX peak was 
identified with UV absorbance at 227 nm, which occurs at between 4-5 minutes 
retention time. The concentration of PTX per injected volume was determined against 
a calibration curve of known PTX concentration in the same mobile phase, and the 
loading level as well as the encapsulation efficiency was determined according to the 
same formulas as Eq. 4.1 and Eq. 4.2 for PTX.  
 
4.2.2.5. In vitro drug release profile of doxorubicin 
The lyophilized DOX-loaded micellar nanoparticles were dispersed in PBS 
buffer (pH 7.4) with a concentration of about 0.5 mg/mL, and placed in a dialysis 
membrane bag with MWCO of 1000 Da. The bag was immersed in a beaker 
containing 50 mL of PBS buffer (pH 7.4), and incubated at 37°C under constant 
shaking at 100 rev/min. At specific time intervals, 1 mL of solution was withdrawn 
from the release medium and fresh PBS buffer was added to the release sink to prevent 
saturation of the sink solution. DOX content in the samples was analyzed using the 
UV¯VIS spectrophotometer at 485 nm wavelength. The in vitro release experiment 
was conducted in 3 parallel batches for peptide carriers having (AF)6 and (AL)6 
hydrophobic tails, and the variation between batches were represented with the error 
bars. 
 
4.2.2.6. Cell culture 
HepG2 cell lines were maintained according to the conditions described in 
Section 3.2.2.8.  
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4.2.2.7. Cytotoxicity analysis 
The cytotoxicity of the least hydrophobic (A12 hydrophobic block) and the most 
hydrophobic ((AF)6 hydrophobic block) peptides were evaluated in the form of 
complex with luciferase DNA against HepG2 cell lines using the standard MTT assay 
protocol as described previously in Section 3.2.2.9. Briefly, cells were seeded onto 96-
well plates at 8,000 cells/well seeding density and incubated for one day. Peptide/DNA 
complexes at N/P ratios of 1, 10, 20, 30, 35, 40, 45 and 50 for the least hydrophobic 
peptide, and at N/P ratios of 1, 5, 8, 10, 12, 15, 18, 20, 25, and 30 for the most 
hydrophobic peptide were prepared in 10 mM phosphate buffer (pH 6.5), as these 
ranges of N/P ratios were used for the gene expression study [152, 157]. The cells were 
then incubated with the sample-containing growth medium (20 mL of peptide, PEI or 
complex solution in 200 mL of fresh growth medium per well). After incubation of 4 
hours, the cells were washed once with PBS buffer, and incubated with the fresh 
medium for further 68 hours. After the treatment, the viability of the treated cells were 
analysed using the protocols described previously in Section 2.3.3.9.  
 
4.2.2.8. Luciferase gene expression 
The in vitro gene transfection of the least and most hydrophobic peptides 
complexes was performed HepG2 cell lines. The cells were seeded onto 24-well plates 
at a density of 8×104 cells/well. After 24 hours, the culture medium was replaced with 
fresh growth medium (supplemented with 10% FBS), and complex solution (50 mL) 
containing 2.5 µg DNA was added to each well. Peptide/DNA complexes at N/P ratios 
of 1, 10, 20, 30, 35, 40, 45 and 50 for the least hydrophobic peptide, and at N/P ratios 
of 1, 5, 8, 10, 12, 15, 18, 20, 25, and 30 for the most hydrophobic peptide were used in 
this experiment. After 4 hours of incubation, the culture media were replaced with the 
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fresh ones, and the cells were further incubated for 68 hours before being analysed 
according to the protocols described in Section 3.2.2.10 previously.  
 
4.2.2.9. Co-delivery of paclitaxel and luciferase gene 
In order to study the possibility of the peptide carrier to induce gene expression 
in the presence of encapsulated drugs, drug-loaded micelles with the most hydrophobic 
tail ((AF)6 hydrophobic block) was used to induce expression of luciferase reporter 
gene in HepG2 cells. In this study, PTX was used as the model drug for the co-delivery 
purpose as it was known to be able to sensitize cancer cells to increase gene 
transfection in various cells [116]. The complexes were formed at N/P ratios 18 and 
25, which were chosen based on the optimum N/P ratios to induce the highest 
luciferase gene expression without PTX. The gene expression level in HepG2 cells was 
evaluated by varying the PTX loading in the complexes between 0.01 to 0.25 mg/L. To 
achieve different PTX loading, different amount of PTX-loaded micelles, and blank 
peptide nanoparticles were pre-mixed before forming the DNA complexes at the 
intended N/P ratios. PTX-loaded peptide nanoparticles used in this study has a loading 
level of 2.1%, and drug encapsulation efficiency of 1.9%, respectively, as analysed by 
HPLC. The complexes were then incubated at room temperature for 30 minutes before 
being incubated with the cells for 4 hours. The luciferase expression level in HepG2 
cells was analyzed at the end of 72 hours as described in Section 3.2.2.10 previously.  
 
4.3. Results and Discussions 
4.3.1. Peptide synthesis and characterization 
Six different peptide designs as given in Table 4.1 were synthesized through 
the standard solid phase peptide synthesis with Fmoc strategy. The success of the 
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synthesis was confirmed by molecular weight characterization of the synthetic via 
MALDI/TOF MS. Table 4.2(a) and 4.2(b) summarized the measured singly ionized 
mass of the peptide samples, which is within a Dalton deviation from the theoretical 
calculated values. 
Table 4.2(a) Effect of Phenylalanine content on the molecular weight and CMC 
Phe/Ala Content [Mw + H]+ CMC (mg/L) 
1/11 3598.4 1100 
2/10 3674.4 300 
3/9 3906.7 200 
6/6 3978.8 42 
 
Table 4.2(b) Effect of Structure of the Hydrophobic amino acid’s side chain on the molecular weight 
and CMC 
Hydrophobic Type [Mw + H]+ CMC (mg/L) 
Phe 3978.8 42 
Leu 3772.1 49 
 
4.3.2. Effect of hydrophobic amino acid content on the CMC of nanostructures 
Oligopeptide nanostructure self-assembly is known as a relatively new class of 
material. Hence, it is of our interest to study the behaviour of the micelization as a 
result of tailoring the hydrophobicity of the tail of the amphiphilic peptide molecule. 
As a generally accepted rule of thumb for amphiphilic molecule design, the more 
hydrophobic the tail is, the stronger the hydrophobic interaction between micelle 
monomers, potentially rendering it to have a lower critical micellization concentration 
(CMC) property. Figure 4.1 shows the CMC estimations of the various peptide 
amphiphiles designed in this study. The effect of the content of phenylalanine as more 
hydrophobic amino acid compared to alanine was firstly investigated. Intuitively, as 
more alanine was replaced by phenylalanine, the CMC was reduced (Table 4.2(a)). In 
addition, the effect of the structure of hydrophobic amino acid was studied by 
replacing phenylalanine, which contains an aromatic side chain with leucine, which 
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contains an aliphatic side chain. In order to gauge the degree of the hydrophobicity of 
these amino acids, one could recall an empirical definition of hydropathy index (HI), 
which scales the degree of lipophilicity of certain amino acids as a positive number. 
The more positive HI scale is, the more hydrophobic the amino acid is [158]. 
According to the HI measure defined by Kyte and Doolittle, Leucine, which has a HI 
value of 3.8, is more hydrophobic than phenylalanine with that of 2.8. Despite Leucine 
residue being more hydrophobic compared to Phenylalanine according to the HI 
values, the CMC of the peptide containing (AL)6 and (AF)6 hydrophobic tails were 
measured to be comparable (42 mg/L vs. 49 mg/L, respectively). This could be due to 
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4.3.3. Particle size and zeta potentials 
As demonstrated in the previous section, micellization self-assembly was 
affected by both the content and the structure of hydrophobic amino acids in the tail of 
the peptide amphiphiles. In addition, these effects on the size of the self-assembly and 
its zeta potential were also studied. Figure 4.2 summarizes the effect of phenylalanine 
content (left) and structure (right) of the amino acids in the hydrophobic tails on the 











Figure 4.2 Effect of Phenylalanine content (left) and Side chain structure (right) on the particle size and 
zeta potentials 
 
From these figures, it can be seen that the size of the resulting assembly was 
significantly affected by both the content of phenylalanine as well as the type of 
hydrophobic amino acids being present in the tail of the amphiphilic molecules. When 
more phenylalanine was used to replace the alanine content, the tail of the amphiphilic 
peptide molecules become more hydrophobic, which provided higher driving force for 
micellar assembly, resulting in a more compact core structure, and hence, less 
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aggregating collodial particles, as shown by the trend formed in Figure 4.2. (left). In 
addition, by varying the structure of the amino acids, we could also demonstrate that 
the degree of hydrophobicity was not the only factor that would affect the size of the 
resulting micellar assembly. We propose that other intermolecular interactions, such as 
p-p stacking, would also play important roles in the resulting size of the assemblies. 
From the same figure, it can also be seen that peptide amphiphiles with phenylalanine 
(F) residues has smaller assembly size than that having leucine (L), even though the 
degree of hydrophobicity of both peptides was rather similar. This implies that F 
residues induces p-p stacking, which in turn resulted in a much more compact core of 
micelles compared to that with L in the core. Moreover, the surface charges of the 
micellar nanoparticles were found to be unaffected by all these variables. This is not a 
surprising phenomenon, as surface charges were only affected by the hydrophilic shell 
of the nanoparticles. Hence, one can intuitively infer that altering the composition of 
the hydrophobic tail alone might not affect the zeta potential of the resulting self-
assembly significantly. 
 
4.3.4. Encapsulation of DOX into core-shell peptide nanoparticles. 
Drug loading level and encapsulation efficiency are one of the important 
characteristics for drug delivery carriers. Therefore, investigating the effect of 
hydrophobic amino acid content and structure, which forms the core of the micellar 
nanoparticles on these properties may provide interesting guidelines for future design 
of oligopeptide micelle nanostructures. Table 4.3(a) and (b) lists these properties as a 
result of varying the phenylalanine content and hydrophobic amino acid structure.  
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Table 4.3(a) Effect of content of phenylalanine on DOX loading  
Phe/Ala Content in the 
Hydrophobic block 
Drug Loading Content 
(%) 
Drug Loading Efficiency 
(%) 
1/11 7.3 10.9 
2/10 10.9 15.2 
3/9 19.9 16.7 
6/6 21.5 19.5 
 
 
Table 4.3(b) Effect of Structure of the Hydrophobic amino acid’s side chain on DOX loading 
Hydrophobic Type Drug Encapsulation 
Efficiency(%) 
Drug Loading Level (%) 
Phe 21.5 (+ 5.2) 19.5 (+1.1) 
Leu 20.3 (+ 3.6) 22.3 (+ 1.2) 
 
From this table, we can see an increasing trend of drug encapsulation efficiency 
and loading levels as more phenylalanine were present in the hydrophobic core of the 
nanoparticles. This is to be expected since increasing the number of phenylalanine 
content would increase the hydrophobicity of the tail, leading to increased interactions, 
hence retention of drug molecules in the core of the micellar nanoparticles. 
Furthermore, Table 4.3(b) does not provide any statistically significant difference in 
these properties between micellar cores formed from phenylalanine- and leucine-
containing hydrophobic tails. One possible reason for this observation was due to the 
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4.3.5. In vitro drug release profile. 
Figure 4.3 provides in vitro release profile of the peptide nanoparticles 
containing DOX with different amino acid side chain structure forming the core of the 
nanoparticles. As can be seen in the figure, peptide nanoparticles having (AF)6 in its 
core releases DOX at a lower rate compared to that having (AL)6. This phenomenon is 
expected owing to the presence of aromatic benzene rings in the core of nanoparticles 
with (AF)6 core. This would provide a p-p interaction between the core of the 
nanoparticles and the drug molecules, hence retaining DOX molecules longer in its 
encapsulated form. This observation was in agreement with the previously reported 
study by Kataoka et al that suggests that p-p interaction helps in increasing drug-
carrier interactions [49]. In addition, in another study, Khoee et al had also shown that 
stronger interactions between nanoparticle cores and drug molecules would reduce 












Figure 4.3. In Vitro drug release profile of (AF)6 (         ) and (AL)6 (        ) hydrophobic blocks 
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4.3.6. Effect of hydrophobicity on gene transfection and cytotoxicity. 
Based on the micellization behaviour and size of the peptide nanostructure 
assembly, the potential biological application of the peptide with ((AF)6 hydrophobic 
block as therapeutic delivery carrier have become apparent. Since we have earlier 
reported that similar peptide design with 12 Alanine residues in the hydrophobic tail 
could transfect various cell lines effectively, it is therefore of our interest to further 
determine if these modified peptides can still function, if not better than, as well as the 
earlier reported peptide nanoparticle assembly [152]. With the cationic block and 
histidine block being kept constant while varying the hydrophobicity of the micellar 
core, it could be ensured that gene condensation of the carrier is kept constant for a fair 
comparison in this study. Figure 4.4 (a) and (b) summarized the luciferase expression 
levels and viability of HepG2 cells when treated with nanoparticles/DNA complexes 
self-assembled from peptide amphiphiles with no phenylalanine in the hydrophobic tail 
(Figure 4.4 (a)) and with 50% phenylalanine content in the hydrophobic tail (Figure 
4.4 (b)). From these figures, it can be seen that the variation of the phenylalanine 
content on the hydrophobic tails, despite affecting the physical characteristic of the 
self-assembly, as well as their respective drug entrapment properties, did not 
significantly alter the gene transfection capability in HepG2 cell lines. This 
observation is expected owing to the same degree of cationic charge as well as 
buffering capacity being present between the two peptides. Interestingly, the cellular 
cytotoxicity profile was significantly different between the two peptides, with the 
peptides containing more phenylalanine residues being more cytotoxic for up to as 
high as twice its original effect.  
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Figure 4.4. Effect of Phenylalanine modification on Luciferase Expression Level (bar) and Cytotoxicity 
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4.3.7. Co-delivery of PTX and Luciferase for synergistic effect. 
The eventual objective of this study was to make use of these designed 
oligopeptide amphiphiles as a cationic micellar self-assembly for simultaneous 
delivery of drug and gene, since it had been reported previously that anticancer drug 
could be used to sensitize cancer cells to induce higher transgene expression [116]. 
Figure 4.5 shows the luciferase expression levels in this cell line when transfected with 
luciferase-encoding plasmid at varying PTX concentration formed at N/P 18 and 25, 
which is the range for optimum transfection efficiency of the peptide with 50% 
phenylalanine substitution in the hydrophobic tail. From this figure, it is shown that 
there exist different set of optimum PTX concentration that would enhance luciferase 
expression levels at different N/P ratios. More importantly, the enhancement of the 
transgene expressions provides the motivation for simultaneous delivery of drugs and 










Figure 4.5. Luciferase Expression level of co-delivered Luciferase plasmid with varying PTX 
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In this chapter, the importance of the hydrophobic amino acid contents on the 
hydrophobic tail of the self-assembling peptide has been revisited. It is shown that this 
hydrophobic contents could strongly affect the self-assembly behaviours, including 
hydrodynamic size, zeta potentials, and CMC. The objective of these modifications 
was firstly to provide empirical design guidelines for the self-assembly behaviour of 
oligopeptide amphiphiles in the context of simultaneous delivery of drugs and genes 
applications. The phenylalanine content of the hydrophobic tail of the peptides had 
been varied systematically to provide some insights for its effect on these properties; in 
addition, replacement of the phenylalanine with other hydrophobic amino acid residues 
having different side chain structure (leucine) was also performed to understand such 
effect on the same properties. Drug entrapment properties were also studied, along 
with the cytotoxicity and reporter transgene expression efficiency capabilities. In 
conclusion, up to 50% phenylalanine substitution on the alanine hydrophobic block 
provided enough driving force to form stable core-shell nanoparticles with small sizes, 
suitable for simultaneous drug and gene delivery. Furthermore, the size of the self-
assembled nanoparticles were also found not to be solely affected by the degree of 
hydrophobicity of the amino acid building blocks alone, but were also affected by 
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V. SELF-ASSEMBLED OLIGOPEPTIDE NANOSTRUCTURES FOR 




The number of clinical trials in gene therapy has increased worldwide to 
overcome serious genetic disorders, such as cancers, cardiovascular diseases, 
neurological diseases, and other types of monogenic disorders. Among all those trials, 
66.5% of the clinical targets for gene therapy were aimed at cancer therapy [160]. With 
the hikes in such trials, non-viral gene delivery vectors also find a rising attention due 
to their non-immunogenic properties as opposed to their viral counterparts. Although 
tremendous efforts have been made to develop efficient therapies, there is still no cure 
for cancer. Drug resistance is one major problem associated with current cancer 
treatments. Combination drug therapies have been attempted to overcome this problem 
in clinic [161-163], but limited success has been achieved. Current developments in 
cancer research suggested that drug resistance is mainly caused by malfunction of 
genes owing to chromosomal alterations in cancer cells [94, 164]. As a result, attempts 
in correcting malfunctioned genes through siRNA or anticancer gene delivery have 
been reported to sensitize cancer cells towards anticancer drugs [165-167]. It has also 
been reported that pretreatment of cells with anticancer drugs such as paclitaxel 
increased transgene expression of reporter genes [153, 168]. Co-delivery of drug and 
gene in the same vehicle not only can improve patient compliance due to the reduced 
number of injections, but can also achieve a synergistic therapeutic effect because both 
drug and gene can be delivered to the same cancer cells or tissues. This delivery 
system may provide a new paradigm in treating cancer.  
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The previous two chapters have been dedicated to designing biocompatible 
peptide-based self-assembly system as a platform biomaterial technology for 
intracellular delivery of gene and/or drug. Macromolecular assemblies made from 
oligopeptides have shown promising biomaterial features owing to ease of synthesis 
and functionalization, as well as their inherent biocompatibility. Moreover, availability 
of the 20 different naturally occurring amino acids with distinct properties allows one 
to design and tailor the properties of peptide assemblies according to their intended 
applications [169-172]. Cationic peptide micelles can also be used for co-delivery of 
drug and gene, if the micellar structure is stable enough. Since the stability of the 
micelle was affected by the strength of the hydrophobic interactions between the 
amphiphiles, systematic investigation on the effect of hydrophobicity of the 
hydrophobic segment of the peptide amphiphiles was conducted to realize this goal. As 
presented in chapter 4, by modifying 50% of the less hydrophobic alanine residues 
with a more hydrophobic phenylalanine residue into the tri-block peptide proposed in 
chapter 3, the CMC of the peptide amphiphiles was reduced significantly, hence 
increasing its aggregation stability for drug encapsulations. This chapter is designed to 
study the potential use of this peptide in simultaneous delivery of anticancer drugs 
(doxorubicin) and gene (p53-encoding gene). 
The modified oligopeptide amphiphile containing 50% phenylalanine residues, 
(AF)6H5K15 (FA32), was synthesized through a solid phase synthesis approach. 
Doxorubicin (DOX) was used as a model anticancer drug since DOX can give 
fluorescence, allowing for study of cellular uptake using a flow cytometer. Drug 
loading capacity of the micelles was evaluated, and in vitro drug release from the 
micelles was investigated. Cytotoxicity of DOX-loaded peptide micelles was evaluated 
against a human hepatocarcinoma (HepG2) cell line in comparison with free DOX. On 
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the other hand, DNA binding ability of the micelles was studied through gel 
retardation assay; and the possibility of using these peptide micelles to transfect gene 
into HepG2 cells was also explored with luciferase reporter gene. The simultaneous 
intracellular delivery of drug and DNA using these micelles was finally demonstrated 
via confocal microscopy, luciferase expression in the presence of DOX, and synergy in 
cytotoxic effect between p53 gene and DOX. 
 
5.2. Materials and Methods 
5.2.1. Materials 
Sodium chloride, sodium dihydrogen phosphate, disodium hydrogen 
phosphate, polyethylenimine (PEI, branched, Mw 25kDa), phenol, agarose, ethidium 
bromide, piperidine, N,N-dimethylacetamide (DMAc), N-methyl morpholine (NMM), 
N-methyl pyrolidone (NMP), triethylamine (TEA), trifluoroavetic acid (TFA), tri-
isopropyl silane (TIS), α-cyano-4-hydroxycinnamic acid (CHCA) crystal, fluorescein 
isothiocyanate (FITC) of fluorescent grade, and 3-[4,5-dimethylthiazolyl-2]-2,5-
diphenyl tetrazolium bromide (MTT) were all purchased from Sigma-Aldrich and used 
as received. Endotoxin-free doxorubicin-HCl (DOX.HCl) was obtained from Boryung 
Pharmaceuticals (Korea) at purity of > 99%, and was used as it is. N,N-
Dimethylformamide (DMF), dichloromethane (DCM), methyl-tert-butyl ether 
(MTBE), acetonitrile (ACN), were bought from Tee Hai Chemicals (Singapore) and 
used as reagents for peptide synthesis. Fluorenylmethoxycarbonyl (Fmoc)-protected 
amino acid monomers, such as Fmoc-Ala-OH, Fmoc-His(Trt)-OH, Fmoc-Lys(Boc)-
OH, Fmoc-Phe-OH, and benzotriazol-1-yl-oxytripyrrolidinophosphonium 
hexafluorophosphate (PyBOP) were obtained from LC Sciences (U.S.A.). Rink Amide 
resin pre-loaded with L-lysine residue at substitution degree of 0.42 mmol/gram was 
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also obtained from LC Sciences (U.S.A.). Phosphate buffered saline (PBS, pH 7.4), 
tris-boric acid-EDTA (TBE) and tris-EDTA (TE) buffers were all bought from 1st 
BASE (Malaysia) and diluted to the intended concentration before use. Reporter lysis 
buffer and luciferin substrate were purchased from Promega (U.S.A.), and DNA 
ladder was obtained from Fermentas (Canada). DMEM growth medium, fetal bovine 
serum (FBS), Hoechst 33258, penicillin and streptomycin were all purchased from 
Invitrogen Corporation (U.S.A.). Plasmid DNA of 6.4 kb size encoding the firefly 
luciferase (pCMV-luciferase VR1255C) driven by cytomegalovirus (CMV) promoter 
was kindly provided by Car Wheeler, Vical (U.S.A.). Plasmid DNA of 5.2 kb size 
encoding wild type p53 tumor suppressor protein (pCMV-p53) driven by CMV 
promoter was purchased from Clontech (Cat No. 631922). Both plasmids were 
amplified in E. coli DH5a strain after transformation of the bacteria, and purified with 
Endofree Giga plasmid purification kit supplied by Qiagen (Netherland). HepG2 cell 
line was obtained from ATCC (U.S.A.) and grown under the recommended conditions 
according to the supplier. CX-rhodamine plasmid labeling kit (Cat No MIR 3100) was 
purchased from Mirus Bio (U.S.A.), and used to label plasmid DNA according to the 
manufacturer’s protocol. Qiagen RNEasy Mini Kit (Cat No: 74104) for total RNA 
isolation was purchased from Qiagen (Netherland). OligodT kit for cDNA synthesis 
was purchased from Fermentas (Canada) and Brilliant SYBR Green PCR Kit (Cat. 
No: #929548) was acquired from Stratagene (U.S.A). 
 
5.2.2. Methods 
5.2.2.1. Peptide synthesis 
The amphiphilic peptide, Ac-(AF)6-H5-K15-NH2 (FA32), was designed and 
synthesized using the standard Fmoc chemistry protocols [154] with an automated 
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Multipep Intavis AG (Cologne, Germany) peptide synthesizer. The peptide synthesis 
was carried out at 50 mmol synthesis scale on the solid Rink Amide MBHA resin 
support, recovered, purified, and characterized according to the protocols described in 
Section 4.2.2.1 in the previous chapter.  
 
5.2.2.2. Critical Micelle Concentration determination 
The CMC of the peptide amphiphile was estimated by fluorescence microscopy 
using pyrene as a probe, according to the protocols described in Section 3.2.2.1 
previously, with the concentration of peptide solution being varied from 0 – 4 mg/L 
[141].  
 
5.2.2.3. Loading of DOX into peptide micelles 
Doxorubicin was loaded into peptide micelles through a membrane dialysis method 
as described in Section 4.2.2.4 and in other literatures [5, 6, 173]. However, in this 
study, the amount of DOX was varied from 2.5 to 5.0 mg in order to optimize the drug 
encapsulation efficiency with the peptide amphiphile FA32. Both LL and EE of DOX-
loaded micelles fabricated from 2 independent batches were calculated according to 
the formulas in Eq. 4.1, and Eq. 4.2. 
 
5.2.2.4. In vitro drug release of DOX 
The release of DOX from the micellar nanoparticles were simulated with 
physiological PBS buffer at pH 7.4. The experiment was conducted according to the 
protocol described in Section 4.2.2.5 previously. 3 independent batches of experiments 
were conducted, and the variation between batches was presented with the error bars. 
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5.2.2.5. Formation of peptide/DNA complexes 
Peptide/DNA complexes were formed by mixing equal volume of peptide and 
DNA solutions under gentle vortexing at various N/P ratios, which is defined as the 
molar ratio of nitrogen content from the primary amine in the lysine residue of peptide 
to phosphorus content of DNA. Peptide solution was originally prepared as a stock in 
10 mM phosphate buffer (pH 6.5) at 10 mg/mL, and further diluted to lower 
concentrations for complex formation at various N/P ratios (1, 5, 8, 10, 12, 15, 18, 20, 
25, and 30). At pH 6.5, the protonable nitrogen at the imidazole ring is expected to be 
in its deprotonated state [174], which is desirable for inducing endosomal escape of the 
peptide/DNA complexes. The nitrogen content of FA32 peptide was calculated to be 
5.28% in weight.  
5.2.2.6. Particle size and zeta potentials measurement 
The particle size and zeta potential of the peptide micelles, micelle/DNA 
complexes, DOX-loaded micelles, as well as DOX-loaded micelle/DNA complexes 
were measured by dynamic light scattering (Brookhaven Instrument Corp., Holtsville, 
NY, U.S.A.) and Zetasizer (Malvern Instrument Ltd., Worchestershire, UK) 
respectively. Luciferase-encoding plasmid DNA was used in this experiment whenever 
complex formation is required. FA32/DNA complexes were formed in 10 mM 
phosphate buffer (pH 6.5) at room temperature at various N/P ratios (i.e. 1, 5, 8, 10, 
12, 18, 20, 25 and 30). All the particle size and zeta potential measurements were 
performed according to the conditions described previously in Section 3.2.2.7. 
5.2.2.7. DNA retardation assay 
Various formulations of FA32/DNA complexes, and DOX-loaded FA32 
micelle/DNA complexes were prepared with N/P ratio ranging from 1 to 3. Similar to 
the previous section, luciferase-encoding plasmid DNA was used for this 
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characterization purpose. Post-equilibration, the complexes were electrophoresed on 
1% agarose gel (stained with 4 μL of 0.5 μg/mL ethidium bromide per 50 mL of 
agarose solution) in 0.5×TBE buffer at 80 mV for 60 minutes. The gel was then 
analyzed on a UV illuminator (Chemi Genius, Evolve, Singapore) to show the position 
of the complexed DNA band relative to that of naked DNA. 
 
5.2.2.8. Cell culture 
HepG2 cell lines were cultured and grown according to the conditions described 
in Section 3.2.2.8.  
 
5.2.2.9. Cellular uptake of DOX 
The uptake of DOX by HepG2 cells was studied quantitatively with a flow 
cytometer (BDS, Netherlands). HepG2 cells were firstly seeded onto 12-well plates at 
a seeding density of 1,000,000 cells/well and grown overnight in DMEM growth 
medium supplemented with 10% FBS and 1% penicillin-streptomycin. On the 
following day, the cells were treated with free DOX and DOX-loaded FA32 micelles 
at DOX concentration of 1 mg/L. After 3 hours of incubation, the cells were washed 
thoroughly with PBS for 5 times, followed by trypsinization and centrifugation at 1200 
rpm for 10 minutes to harvest the cells as pellets. The cells were re-suspended in PBS, 
and measured for its fluorescent intensity per cells with the flow cytometer. The 
fluorescent intensity measurement was referenced to that given by HepG2 cells 
without any drug treatments to eliminate the possibility of auto-fluorescent 
phenomenon produced by the cells. The measurements were done with excitation and 
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emission wavelengths of 532 nm and 595 nm respectively, as described in the 
literature [5]. 
As a qualitative comparison, an independent set of experiments was performed 
by confocal imaging of HepG2 cells treated under the same conditions as above. 
Briefly, HepG2 cells were seeded onto a 4 well-cover slip borosilicate glass chamber 
(NUNC) at a seeding density of 40,000 cells/well and grown overnight. After 24 hours, 
the cells were incubated with free DOX, DOX-loaded or FA32 micelles at DOX 
concentration of 1 mg/L. After 3 hours of incubation, the cells were washed thoroughly 
with PBS and imaged under a confocal microscope (Zeiss LSM Duo Inverted, U.S.A.) 
with excitation and emission wavelengths of 532 nm and 595 nm respectively. 
 
5.2.2.10. Cytotoxicity of FA32, FA32/DNA complexes, DOX and DOX-loaded 
micelles 
The cytotoxic effect of FA32, FA32/DNA complexes, free DOX and DOX-
loaded micelles were tested with MTT viability assay. Briefly, HepG2 cells were 
seeded onto 96-well plates at a seeding density of 8,000 cells/well and grown 
overnight. On the following day, the cells were treated with blank FA32 or FA32/DNA 
complexes at N/P 1, 5, 8, 10, 12, 15, 18, 20, 25, and 30 (20 mL of peptide or complex 
solution in 200 mL of growth medium). In the case of blank peptides, to achieve the 
same concentration of peptide as the complex, an equivalent volume of phosphate 
buffer was added instead of DNA solution. For blank peptide and peptide/DNA 
complex samples, peptide concentration was 0.04, 0.20, 0.32, 0.40, 0.48, 0.60, 0.72, 
0.80, 0.99 and 1.19 mg/mL at each N/P ratio. For free DOX and DOX-loaded micelles, 
DOX concentration tested was 0.01, 0.05, 0.1, 0.25, 0.5, 1, 2.5, 5, 10, and 20 mg/L. 
After 4 hours of incubation, the cells were washed once with PBS, and grown for 
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another 68 hours. The growth medium was then replaced with fresh growth medium 
(100 mL) and MTT solution in PBS (10 mL, 5 mg/mL), and the cells were further 
incubated for 4 hours. Following that, the medium was replaced with DMSO (150 mL) 
to dissolve the formazan crystals from internalized MTT. An aliquot of 100 mL was 
taken from each well and transferred into a new 96-well plate. The samples were then 
assayed with a microplate reader (Biorad, California, U.S.A.) according to the protocol 
described previously in Section 3.2.2.9. 
 
5.2.2.11. In vitro gene expression 
To evaluate the efficiency of the peptide micelles to induce gene expression in 
HepG2 cells, the luciferase reporter gene was used to form peptide/DNA complexes at 
various N/P ratios. The cells were seeded onto 24-well plates at a density of 8×104 
cells/well, and cultivated in 0.5 mL of DMEM growth medium supplemented with 
10% FBS and 1% penicillin-streptomycin. After 24 hours, the culture medium was 
replaced with the fresh growth medium containing 10% FBS, and complex solution 
(50 mL) containing 2.5 µg of DNA was added to each well. After 4 hours of incubation 
with peptide/DNA complexes, the culture media were replaced with the fresh ones. 
The culture media were removed after 68 hours, and the cells were washed with 0.5 
mL of PBS, and assayed for the extent of luciferase gene expression using the methods 
described in Section 3.2.2.10. In all these experiments, naked DNA-transfected cells 
were used as negative control, and cells transfected with PEI/DNA formed at N/P 10, 
the optimal N/P ratio, at which PEI induced high gene expression yet provided more 
than 50% cell viability, were employed as positive control. The experiment was 
conducted with 6 replicates, and the standard deviations between replicates were 
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represented as the error bars. Statistical analysis was performed using Student’s t-test. 
Differences were considered statistically significant with p < 0.05. 
 
5.2.2.12. Co-delivery of drugs and gene 
a. Imaging of co-delivery of model drug and gene 
As a proof of concept, co-delivery of drug and gene was performed using FITC 
as a model hydrophobic drug and rhodamine-labeled blank plasmid as a model gene. 
Briefly, FITC was loaded into FA32 micelles by the membrane dialysis method as 
described above for DOX loading. The loading efficiency of FITC was tested 
according to the reference [175]. FITC-loaded FA32 nanoparticles were complexed 
with DNA at N/P 18, and the complex solution was allowed to stabilize for 30 minutes 
prior to gene transfection. After 4 hours of incubation with the DNA complexes, the 
cells were treated with Hoechst 33258 solution (5 mg/mL) for 15 minutes, followed by 
thorough washing with PBS before being imaged with the confocal microscope. In 
another experiment, after 4 hours of incubation, the cells were further incubated with 
fresh growth medium for another 20 hours, before being treated with Hoechst 33258 
and imaged under the confocal microscope. 
b. In vitro gene expression for co-delivery of DOX and luciferase reporter gene 
In order to study the possibility of the peptide carrier to induce gene expression 
in the presence of encapsulated drugs, DOX-loaded FA32 micelles were used to 
induce expression of luciferase reporter gene in HepG2 cells. The complexes were 
formed at N/P ratios 18 and 25, which were chosen based on the optimum N/P ratios 
to induce the highest luciferase gene expression without DOX. The gene expression 
level in HepG2 cells was evaluated by varying the DOX loading in the complexes 
between 0.01 to 0.25 mg/L. To achieve different DOX loading, different amount of 
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DOX-loaded FA32 micelles, and blank FA32 peptide were pre-mixed before forming 
the DNA complexes at the intended N/P ratios. The complexes were then incubated at 
room temperature for 30 minutes before being incubated with the cells for 4 hours. 
The luciferase expression level in HepG2 cells was analyzed at the end of 72 hours as 
described in Section 5.2.11.  
c. Co-delivery of p53-encoding plasmid with DOX. 
Co-delivery of p53 (a therapeutic gene) and DOX was used to test the synergy in 
the anti-tumor activities between both therapeutics in HepG2 cells. The complexes 
were formed at various N/P ratios and at the fixed DOX content of 0.01 mg/L 
according to the previously described protocols. HepG2 cells, seeded onto 96-well 
plates at density of 8,000 cells/well, and were then treated with the complexes for 4 
hours, followed by further incubation for 68 hours with fresh growth medium. Cell 
viability after the transfection with DOX-loaded FA32 micelle/p53-encoding plasmid 
was analyzed with MTT assay at the end of 72 hours, in comparison with FA32 
micelle/p53-encoding plasmid complexes, FA32 micelle/luciferase-encoding plasmid 
complexes and free DOX (0.01mg/L). In addition, to measure the extent of p53 
mRNA expression level upon transfection in the presence of DOX, quantitative real 
time PCR (RT-PCR) technique was employed. For this purpose, HepG2 cells were 
seeded on a 24-well plate at density of 80,000 cells/well. 24 hours post-seeding, cells 
were transfected with complexes containing p53 gene, or control plasmid. After 48 
hours of transfection, total RNA was isolated from the cells by using Qiagen RNEasy 
Mini Kit (Cat No: 74104). The RNA was reverse transcribed with OligodT 
(Fermentas) according to the manufacturer’s protocol. Real-time PCR was performed 
on 1 mL of cDNA with the Brillian SYBR Green PCR Kit (Stratagene) according to 
the manufacturer’s recommended instructions. The p53 primers used for the RT-PCR 
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experiment were as follows: Forward:   5’-CCGCAGTCAGATCCTAGCG-3’; 
Reverse: 5’-AATCATCCATTGCTTGGGACG-3’. [176]. And the actin primers used 
were as follows: Forward: 5’-TACCTCATGAAGATCCTCACC-3’; Reverse: 5’-
TTTCGTGGATGCCACAGGAC-3’ [177]. Amplification conditions are as follows: 
40 cycles of denaturation at 95°C for 30s, annealing at 58°C for 30s, and extension at 
72°C for 30s with a Bio-Rad iCycler.  
 
5.3. Results and Discussions 
5.3.1. Peptide synthesis and Self-assembly 
The FA32 peptide formed micellar nanoparticles by direct dissolution into an 
aqueous solution. Table 5.1 briefly summarized the characteristic molecular weight of 
the synthetic peptide, together with its micellization property. The existence of CMC 
for this peptide, as described in the previous chapter, brings about the evidence for the 
formation of micellar self assembly.  
 
Table 5.1 Characterization of FA32 peptide amphiphiles 
Peptide 
Mw (Da)* Purity (%) CMC (mg/mL) 
Ac-(AF)6-H5-K15-NH2 (FA32) 3977.915 87-93 0.042 
* Molecular weight values given as [M+H]+, measured via MALDI-TOF MS 
 
5.3.2. Particle size and Zeta potential analysis 
As shown in Figure 5.1, the size of FA32 micelles was much smaller (100-250 
nm) than the original AK32 micelles (787 nm) [152]. This may be attributed to the 
stronger hydrophobic interaction upon the introduction of more hydrophobic amino 
acids, hence forming micellar aggregates with closer packing density. On the other 
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hand, these new peptides had the same cationic length as the original peptide AK32. 
Therefore, one could expect that FA32 and AK32 micelles would have a similar zeta 










Figure 5.1 Size and zeta potentials of FA32 micelles (Blank micelles: Size , Zeta potential  , 
DOX-loaded micelles: Size , Zeta potential ). 
 
 
After DNA binding or DOX loading, the size of peptide micelles was increased, 
but their zeta potential did not change much (Figure 5.1). In a similar manner, the size 
of DOX-loaded micelle/DNA complexes was also increased when compared to blank 
peptide micelle/DNA complexes; and as expected, their zeta potential was similar, 
since both DOX-loaded micelles and blank micelles had a similar zeta potential. In 
particular, the size of DOX-loaded FA32 micelle/DNA complexes was below 200 nm 
at N/P 15 or above, and at these N/P ratios, their zeta potential was around 20 mV. The 
small size and net positive surface charge of FA32 micelles may provide desirable 
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5.3.3. DOX loading and in vitro drug release 
Fabrication of DOX-loaded micelles was firstly optimized for drug loading and 
encapsulation efficiency by varying the initial drug loading. As listed in Table 5.2, the 
highest loading level and loading efficiency of DOX was achieved at the initial drug 
loading of 5.0 mg. In particular, at this initial drug loading, final DOX loading was 
20%, and the loading efficiency was 22%. The DOX loading level achieved by FA32 
was much higher than those obtained by the micelles that we reported previously, in 
which the cores of the micelles were made of poly(lactide-co-glycolide) (~8%) [6] or 
undecanoic acid (~4%) [5]. From Table 5.2, it can also be observed that as the initial 
amount of DOX was reduced from 5.0 to 2.5 mg, the loading level and encapsulation 
efficiency of DOX decreased significantly.  
 
Table 5.2 Effect of initial DOX content on its encapsulation efficiency and loading level in peptide 







5.00 21.5 (+ 5.2) 19.5 (+1.1) 
3.33 1.9 (+0.7) 1.5 (+ 0.3) 
2.50 1.7 (+0.7) 0.8 (+0.2) 
 
 
In vitro release profile of DOX from FA32 micelles is shown in Figure 5.2. DOX 
release occurred in a controlled manner without obvious initial burst during the first 12 
hours, indicating that DOX molecules were well encapsulated within the micelles. The 
amount of DOX released from FA32 micelles over the first 18 hours was 35%, after 
which the DOX release became much slower. In comparison to our previous study 
with thermal and pH-sensitive micelle fabricated from Poly-b-(NiPAm-co-DMAm)-b-
Poly(UA) [5], the release of DOX with FA32 is relatively slower; The polymer micelle 
released DOX between 35-80% at different pH conditions, while FA32 released DOX 
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up to 35% under physiological pH. This is possibly due to the hydrophobic interaction 
between benzene rings on the Phenylalanine side chain with the DOX molecules. In 
addition, the presence of histidine block renders the nanoparticle core more 














Figure 5.2 In vitro drug release profile of DOX-encapsulated FA32 peptide micelles (Error bars 
represent standard deviation between 3 independent batches). 
 
 
5.3.4. Cellular uptake of DOX 
DOX molecules emit fluorescent signals at 595 nm when excited at 532 nm 
[24]. This allows for investigation of DOX internalization through confocal 
microscopy or flow cytometry. Figure 5.3a displays confocal images of HepG2 cells 
treated with DOX (i) or DOX-loaded micelles (ii) at DOX concentration of 1 mg/L for 
3 hours. Stronger fluorescent signals were observed in the cells treated with DOX-
loaded peptide micelles as compared to those treated with free DOX, indicating that 
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the cells took up more DOX molecules when they were delivered by FA32 micelles. In 
addition, free DOX molecules delivered without any carrier were localized in the 
nucleus of the cells after 3 hours of incubation, where DOX could exhibit its anti-
mitotic activity through intercalation with the cellular DNA. On the other hand, DOX 
molecules delivered by the micelles were mostly found in the cytoplasm of the cells 
during the same incubation period. This is because DOX-loaded micelles were too 
large to enter the nucleus directly. And as only a small portion of DOX molecules were 
released from these micelles during the first three hours of incubation (Figure 5.2), 
smaller amount of free DOX molecules were available in the cell’s cytoplasm to 
diffuse to its nucleus.  
Furthermore, quantitative analysis of cellular uptake of DOX was performed 
using a flow cytometer. As shown in Figure 5.3b, there was about one-fold increment 
in the fluorescent intensity per cell when DOX molecules were internalized in the 
encapsulated form, suggesting that the cells took up twice the amount of DOX 
molecules when they were delivered by the micelles. The presence of net positive 
charge on the surface of DOX-loaded micelles may cause such increment in drug 
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Figure 5.3 (a) Confocal images of HepG2 cells and (b) Fluorescent intensity of HepG2 cells treated 
with (i - ) free DOX, (ii - ) DOX-loaded FA32; DOX fluorescence measured at excitation and 
emission wavelengths of 532 nm and 595 nm respectively. DOX concentration: 1 mg/L. 
 
5.3.5. DNA retardation analysis 
The DNA binding ability of peptide was studied through gel retardation assay. 
As shown in Figure 5.4 (lanes 3-5), FA32 peptide was able to bind DNA efficiently, 
and the complete retardation of DNA mobility was achieved at N/P 2. Complexes 
formed at N/P 1 shows incomplete complexation (Figure 5.4, lane 3), which is also 
supported by the negative zeta potential value of peptide/DNA complexes formed at 
this N/P ratio. These findings are in agreement with the original unmodified AK32 
(a)-i (a)-ii 
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peptide since all peptides had the same length of cationic lysine block [152]. In 
addition, the gel retardation assays from the DNA complexes formed with DOX-
loaded micelles also yielded a similar retardation profile (Figure 5.4 lane 6-8). This is 
because DOX-loaded micelles had a similar zeta potential value when compared to the 








Figure 5.3 Electrophoretic mobility of DNA in peptide/DNA complexes. Lane 1: DNA ladder; Lane 2: 
naked DNA; Lanes 3-5: FA32/DNA complexes at N/P 1, 2 and 3 respectively; Lanes 6-8: FA32-
DOX/DNA complexes at N/P 1, 2 and 3 respectively. 
 
5.3.6. Cytotoxicity of FA32, FA32/DNA complexes, free DOX and DOX-loaded 
micelles 
As reflected in Figure 5.5, FA32 peptide exhibited slightly higher cytotoxicity 
at higher concentrations. At N/P 30, the highest N/P ratio used in this study, the 
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Figure 5.5 Viability of HepG2 cells after incubation with FA32 peptide/DNA complexes ( ) and 
blank FA32 peptide ( ). Peptide concentrations at each N/P ratios: 0.04, 0.20, 0.32, 0.40, 0.48, 0.60, 










Figure 5.6 Viability of HepG2 cells after incubation with free DOX ( ) and DOX-loaded FA32 
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Figure 5.6 shows the viability of HepG2 cells after being treated with free 
DOX and DOX-loaded peptide micelles. The IC50, a drug concentration, at which 50% 
cells were killed, of free DOX and DOX delivered by FA32 micelles was estimated to 
be approximately 0.25 mg/L, and 1.8 mg/L, respectively. Although peptide micelles 
delivered a greater amount of DOX molecules into the cells as compared to the free 
DOX formulation (Figure 5.3), a higher IC50 value was observed for DOX-loaded 
micelles. One possible reason is the slow release of DOX from the micelles, as 
evidenced by the in vitro drug release profiles shown in Figure 5.2. It is known that 
DOX suppresses the growth of cancer cells through intercalation with cellular DNA, 
inducing the cells to undergo apoptosis [179]. Therefore, DOX has to be released from 
the micelles so that it can enter the nucleus to achieve its therapeutic function. Since 
DOX release from the micelles was sustained, DOX-loaded micelles with a higher 
initial DOX content were needed to release the same amount of DOX as the free DOX 
formulation, resulting in a higher IC50. Similar findings were also reported in other 
types of micelles [119, 180, 181]. 
 
5.3.7. In vitro gene expression 
The above studies showed that these peptide micelles provided high loading 
capacity for DOX, and delivered DOX into the cells efficiently. To examine the 
possibility of using these micelles to deliver DNA, luciferase expression levels in 
HepG2 cells were analyzed after the cells were transfected with micelle/DNA 
complexes in the presence of serum (Figure 5.7). The highest luciferase expression 
level induced by FA32 was 3.2 ´ 108 RLU/mg protein at N/P 18, which was 
comparable to those mediated by AK32 and PEI (1.2 ´ 108 RLU/mg protein at N/P 10 
and 1.9 ´ 108 RLU/mg protein at N/P 10 respectively).  
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Figure 5.7 Luciferase expression level in HepG2 cells after transfected with FA32/DNA complexes at 
various N/P ratios. (n = 6 replicates). 
 
5.3.8. Simultaneous delivery of model drug and gene 
To prove that FA32 peptide micelles are able to deliver drug and gene into the 
same cells, hydrophobic FITC and rhodamine-labeled DNA were used as the model 
drug and gene. Encapsulation of FITC was done with initial feed loading of 30% (3 mg 
FITC/10 mg FA32) with the same dialysis method used for DOX encapsulation. The 
final loading efficiency of the micelle used in this experiment was tested to be 13.5% 
(+ 0.8%), with its loading level measured at 5.0% (+ 1.0%). FITC-loaded 
micelle/DNA complexes were then formed at N/P 18, at which gene transfection was 
the most efficient. Internalization of these complexes into HepG2 cells was observed 
via confocal microscopy. After 4 hours of incubation, both FITC and DNA were co-
localized in the cytoplasm and periphery of the nucleus (the yellow regions in Figure 
5.8), suggesting successful co-delivery of the physically-entrapped FITC and 
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were dissociated from the FITC-loaded micelles, as evidenced by the distinct red and 
green regions in Figure 5.8. These findings suggest the possibility of using these 








Figure 5.8 Confocal images of HepG2 cells treated with FITC-loaded FA32 micelle/rhodamine-labeled 
DNA complexes formed at N/P 18 for 4 hours. Left: cells imaged right after 4 hours of transfection; 
Right:  cells observed after another 20 hours of incubation post-transfection. 
 
5.3.9. Co-delivery of DOX and Luciferase- or p53-encoding plasmid 
Having demonstrated the capability of FA32 micelles to carry the model drug 
and gene simultaneously, we attempted to quantify the extent of gene expression when 
it was delivered together with DOX. Figure 5.9a shows luciferase expression levels in 
HepG2 cells when the reporter gene was delivered using FA32 micelles with DOX 
loaded in the cores. The complexes used were formed at N/P 18 and 25 (optimal gene 
expression levels as observed in Figure 5.9), while the drug concentration was varied 
from 0.01 to 0.25 mg/L. Luciferase expression was still observed in the presence of 
DOX although the expression level appeared to be reduced especially when DOX-
loaded FA32 micelle/DNA complexes were formed at N/P 18. This phenomenon was 
also reported by Qiu LY and Bae YH [119]. The reduced luciferase expression level 
could be attributed to the cytotoxic properties of DOX. DOX molecules could 
24 hrs
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intercalate in between the base pairs of DNA, and inhibit macromolecular biosynthesis 
[182], resulting in a cytotoxic effect. The cytotoxicity of DOX might impede the 























Figure 5.9 (a) Luciferase Expression level in HepG2 cells after transfected with DOX-loaded FA32 
micelle/luciferase-encoding plasmid with varying DOX concentrations at N/P 18 ( ) and 25 ( ), 
and (b) Viability of HepG2 cells after transfected with FA32 micelle/luciferase-encoding plasmid 
complexes ( ), FA32 micelle/p53-encoding plasmid complexes ( ), DOX-loaded FA32 micelle/p53-
encoding plasmid complexes (DOX content: 0.01 mg/L) ( ) and pure DOX (0.01 mg/L, last bar). 
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The use of FA32 micelles for co-delivery of a therapeutic gene (i.e. p53-
encoding plasmid) and DOX has been demonstrated,, and the synergy between the two 
therapeutics, at both end-point cytotoxicity level and at mRNA expression level, 
against HepG2 cell line has also beejn evaluated.. The p53 gene is a tumor suppressive 
gene, which can inhibit cell proliferation through apoptosis and/or G1-cell cycle arrest 
in mammalian cells [183]. Therefore, through such cell senescence and apoptosis, the 
p53 gene expression in cells could lower cell viability. As shown in Figure 5.9b, p53 
gene transfection indeed reduced the viability of HepG2 cells especially at N/P 18 and 
above, when compared to luciferase (irrelevant) reporter gene transfection (black bars 
versus white bars). More importantly, co-delivery of p53 gene and DOX using FA32 
micelles showed much higher cytotoxicity against HepG2 cells at N/P 18 and above 
when compared to FA32 micelle/p53-encoding plasmid complexes and pure DOX 
treatment alone. This indicates that the co-delivery of p53 gene and DOX using FA32 
micelles achieved a synergistic effect in suppressing the proliferation of HepG2 cells.  
The synergy between the two therapeutic agents was further supported by the 
increased p53 mRNA expression level in the presence of DOX. At the mRNA 
expression level, the mRNA profile was analyzed from HepG2 cells after being 
transfected with p53 gene in the presence of DOX. Its level was further compared with 
various control groups, i.e. untreated HepG2 cells, HepG2 cells treated with FA32-
DOX micelles (at DOX concentration of 0.01 mg/mL), and HepG2 cells transfected 
with luciferase-encoding (irrelevant) plasmid to serve as measures for the baseline 
endogenous p53 mRNA expression. In addition, p53 mRNA profile of HepG2 cells 
after being transfected with p53 gene alone (without DOX) was also analyzed to 
provide comparison for the synergy of the therapeutics. The p53 mRNA expression 
profile was summarized in Figure 5.10, and it can be seen that statistically significant 
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difference in the mRNA profile between the control and sample groups was observed; 













Figure 5.10 mRNA expression level of p53 transfected HepG2 cells without DOX ( ) and with DOX 
( ). Control groups: HepG2 cells treated with FA32-DOX micelle (at DOX concentration of 0.01 
mg/mL, DOX-0.01), and HepG2 cells transfected with luciferase-encoding (irrelevant) plasmid (  ). 
Sample size, n = 3, data were referenced to the p53 mRNA expression level of untreated HepG2 cell 
control group. 
 
This observation suggests the synergistic effect between p53 gene and DOX, which 
could be due to the mechanism of DOX’s anticancer activity. It was reported by Wang 
et al that DOX induced apoptosis of tumor cells through the activation of p53-
dependent apoptosis pathways [184]. Even though HepG2 cells are known to have 
non-mutated endogenous wild-type p53 gene [185], its accumulation in the cells is 
known to be relatively low under normal conditions [186]. Incubation with 0.01 mg/L 
of DOX could only activate as much p53 apoptosis pathway to result in 97% cell 
viability upon the treatment (Figure 5.9). Moreover, the level of endogenous p53 
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endogenous p53 expression for the treatment. However, the co-delivery of DOX (of 
the same amount) with exogenous p53 gene, the increased level of cellular p53 mRNA 
through the exogenous p53 gene expression was achieved. As such, this could have 
cause synergistic activation of the p53-dependent apoptosis and/or senescence, leading 
to much lower cell viability, i.e. 45% (Figure 5.9, at N/P 25).  
 
5.4. Conclusions 
In this chapter, co-delivery of therapeutic anticancer drug and gene was 
demonstrated and evaluated for their synergy using FA32 peptide designed and studied 
in Chapters 3 and 4. FA32 easily self-assembled in an aqueous solution to form 
cationic micelles at low concentrations. The self-assembly of FA32 peptide molecules 
resulted in small micelles with particle size of about 100 nm. These micelles provided 
high capacity for loading DOX, and delivered the drug into the cells efficiently. In 
addition, these micelles were capable of condensing DNA, and delivering it into 
HepG2 cells with high efficiency (of the same order as PEI gold standard). More 
importantly, it has been demonstrated that FA32 micelles were able to deliver 
hydrophobic drug and gene simultaneously into the same cells. The co-delivery of 
DOX and p53-encoding plasmid using FA32 micelles achieved a synergistic effect in 
suppressing the proliferation of HepG2 cells when compared to individual treatments 
of pure DOX and FA32 micelle/p53-encoding plasmid complexes. These findings 
suggest that FA32 micelles can be an effective carrier to deliver hydrophobic 
anticancer drug and gene simultaneously for improved cancer therapy.  
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VI. GALACTOSE-COATED SELF-ASSEMBLED OLIGOPEPTIDE 
NANOSTRUCTURES VIA ELECTROSTATIC ADSORPTION FOR 
TARGETED SIMULTANEOUS DELIVERY OF ANTICANCER 
DRUGS AND GENES 
 
6.1. Introduction 
In Chapter 2, thorough discussions on how limitations from conventional 
chemotherapy could possibly be overcome by proper rational design of therapeutic 
delivery carrier at the nano-size have been reviewed. This applies to an extensive 
library of chemotherapeutic agents, including drugs [5], genes [152], or proteins [187]. 
With such a design, one could first make use of the nano-size property of a 
biodegradable and biocompatible vehicle to achieve the first stage of chemotherapeutic 
targeting into cancer sites, hence minimizing exposure of highly potent 
chemotherapeutic agent to non-cancerous cells. This phenomenon has been well-
known as EPR effect, and was coined for the first time in 1986 by Maeda and his team. 
Even though EPR effect has been widely accepted to provide passive targeting 
capabilities, there are many interests building up in providing better targeting 
capabilities of the nanocarriers for enhanced targeted drug delivery towards cancer 
cells. This could be achieved by attaching a specific targeting ligand that could 
recognize over-expressed receptor proteins on cancer cells’ surface. Some examples of 
this ligand is folic acid (targeting folic receptor) [5, 189], RGD peptide (targeting 
integrin receptor) [128], galactose moiety (targeting Asialoglycoprotein receptor) [78], 
etc. By presenting such ligands on the surface of nanoparticle that contains 
chemotherapeutic agents, they could then actively recognize the complementary 
binding receptors over-expressed on cancer cells upon extravasation towards tumor 
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sites. The benefit of such strategy is evident, as more nanoparticles on the tumor sites 
could be internalized by cancer cells through receptor-mediated endocytosis [189].  
It has earlier been reported that cationic micelles or liposomes could be used to 
co-deliver anticancer drugs and genes to achieve synergistic therapeutic effect [116, 
119, 153, 190].  Chapter 5 has provided some basis for anticancer therapy strategy in 
using the peptide micellar nanoparticles being studied in the preceding two chapters as 
a simultaneous delivery vehicle for doxorubicin and p53 gene. Combined treatment of 
cancer cells with drugs and p53 gene using viral vectors was earlier reported to 
effectively suppress the growth of cancer cells, despite the state of the endogenous p53 
gene in the cancer cells [191]. The simultaneous delivery performed in Chapter 5 has 
shown to give a synergistic anti-proliferative effect on a liver cancer (HepG2) model 
cell line. The aim of this chapter is then to provide an active targeting scheme for an 
improved cancer treatment. And to build upon the works presented in Chapter 5, the 
relevant ligand of choice in this Chapter is galactose moiety that could be recognized 
by ASGPR over-expressed by HepG2 model cell line. Another reason to use galactose 
is owing to its extensive use in literature with proven capabilities to target the receptor 
of interest [34, 35, 78]. 
Green et al has recently reported that electrostatic interaction could be used as a 
strategy to provide targeted delivery of gene using cationic polymer vehicle [128]. 
Since cationic micelles was used to condense DNA on the surface, chemical 
conjugation of targeting ligand on the surface of the micelle prior to DNA adsorption 
might cause undesired random masking of the ligand by the adsorbed DNA molecules, 
as well as possible charge reduction for DNA binding. It might therefore be 
advantageous to adopt electrostatic interaction in attempting to achieve targeted 
simultaneous delivery of anticancer drugs and genes with cationic micelles. In this 
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study, a short glycopeptide comprising a D-galactose moiety and a negatively-charged 
amino acid (L-Glutamic Acid) block was designed and synthesized to be used as the 
active targeting ligand. In a similar manner that DNA was adsorbed onto the cationic 
micelles, this ligand was also electrostatically-attached onto the positively-charged 
DNA/micelle complex. The formation of the targeted delivery vehicle for simultaneous 
delivery of drug and gene is proposed in Figure 6.1. 
 
 
Figure 6.1 Schematic diagram for Electrostatically-driven galactosylation of peptide/DNA complex. 
 
6.2. Materials and Methods 
6.2.1. Materials 
Sodium chloride, sodium dihydrogen phosphate, disodium hydrogen 
phosphate, sodium hydroxide pellet (NaOH), polyethylenimine (PEI, branched, Mw 
25kDa), piperidine, N,N-dimethylacetamide (DMAc), N-methyl morpholine (NMM), 
N-methyl pyrolidone (NMP), triethylamine (TEA), trifluoroavetic acid (TFA), tri-
isopropyl silane (TIS), α-cyano-4-hydroxycinnamic acid (CHCA) crystal, and 3-[4,5-
dimethylthiazolyl-2]-2,5-diphenyl tetrazolium bromide (MTT), and lactobionic acid 
Cationic micelle 
+ 
+ + + + 
+ 
+ + 















   
GalGE12 
ligand 
DNA and Ligand adsorption schematic 
Peptide/DNA 
complex 
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were all purchased from Sigma-Aldrich and used as received. Endotoxin-free 
anticancer drugs, doxorubicin-HCl (DOX.HCl) was obtained from Boryung 
Pharmaceuticals (Korea) at purity of > 99%, and used as it is. N,N-Dimethylformamide 
(DMF), dichloromethane (DCM), methyl-tert-butyl ether (MTBE), acetonitrile (ACN), 
were bought from Tee Hai Chemicals (Singapore) and used as reagents for peptide 
synthesis. Fluorenylmethoxycarbonyl (Fmoc)-protected amino acid monomers, such as 
Fmoc-Ala-OH, Fmoc-Glu(trt)-OH, Fmoc-Gly-OH, Fmoc-His(Trt)-OH, Fmoc-Leu-
OH, Fmoc-Lys(Boc)-OH, Fmoc-Phe-OH, and benzotriazol-1-yl-
oxytripyrrolidinophosphonium hexafluorophosphate (PyBOP) were obtained from LC 
Sciences (U.S.A.). Rink Amide resin pre-loaded with L-lysine residue at substitution 
degree of 0.27 mmol/gram, and Wang resin pre-loaded with L-glycine at substitution 
degree of 0.42 mmol/gram were also obtained from LC Sciences (U.S.A.). N-
hydroxysulfosuccinimide (sulfo-NHS), 1-Ethyl-3-[3-dimethylaminopropyl] 
carbodiimide hydrochloride (EDC), and 2-(N-morpholino)ethanesulfonic acid (MES) 
buffer powder were purchased from pierce and used as received. Phosphate buffered 
saline (PBS, pH 7.4), was bought from 1st BASE (Malaysia) and diluted to the 
intended concentration before use. Reporter lysis buffer and luciferin substrate were 
purchased from Promega (U.S.A.). DMEM growth medium, fetal bovine serum (FBS), 
penicillin and streptomycin were all purchased from Invitrogen Corporation (U.S.A.). 
Plasmid DNA of 6.4 kb size encoding the firefly luciferase (pCMV-luciferase 
VR1255C) driven by cytomegalovirus (CMV) promoter was kindly provided by Car 
Wheeler, Vical (U.S.A.). It was amplified in E. coli DH5a strain after transformation 
of the bacteria, and purified with Endofree Giga plasmid purification kit supplied by 
Qiagen (Netherland). Plasmid DNA of 5.2 kb size encoding wild type p53 tumor 
suppressor protein (pCMV-p53) driven by CMV promoter was purchased from 
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Clontech (Cat No. 631922). Both plasmids were amplified in E. coli DH5a strain after 
transformation of the bacteria, and purified with Endofree Giga plasmid purification 
kit supplied by Qiagen (Netherland). HepG2 cell line was obtained from ATCC 
(U.S.A.) and grown under the recommended conditions according to the supplier. 
Qiagen RNEasy Mini Kit (Cat No: 74104) for total RNA isolation was purchased from 
Qiagen (Netherland). OligodT kit for cDNA synthesis was purchased from Fermentas 




6.2.2.1. Peptide synthesis 
Two peptide sequences used in this study were synthesized using the standard 
Solid Phase Peptide Synthesis (SPPS) with the Fmoc protection strategy in an 
automated Multipep Intavis AG (Cologne, Germany) peptide synthesizer. These 
peptide sequences are Ac-AFAFAFAFAFAFHHHHHKKKKKKKKKKKKKKK-NH2 
(FA32), and LBA-GGGEEEEEEEEG-OH (GE12). FA32 peptide was grown on a rink 
amide resin preloaded with L-lysine residue (0.27 mmol/g), while GE12 peptide was 
grown on wang resin preloaded with L-glycine residue (0.43 mmol/g). The synthesis 
was carried out at 50 mmol scale on a rink amide MBHA resin support. At the end of 
the synthesis, the peptides were cleaved, recovered, and characterized according to the 
protocols described previously in Section 4.2.2.1. 
 
6.2.2.2. Galactosylation of negatively-charged peptide 
Galactose moiety was added onto GE12 peptide by amide bond linking 
between carboxyl terminal of galactose bearing lactobionic acid and N-terminal of 
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GE12 peptide with sulfo-NHS and EDC as the crosslinker, via formation of a semi-
stable amine reactive sulfo-NHS ester intermediate formation.  Briefly, lactobionic 
acid (21 mg, 10 mole eq. of peptide) was pre-activated with EDC (63.7 mg, 5 mole eq. 
of acid) in the presence of sulfo-NHS (56.2 mg, 5 mole eq. of acid) for approximately 
15 minutes in 10 mL MES 1X buffer (pH~5). GE12 peptide solution (1 mg/mL, 
10mL) dissolved in PBS 1X buffer (pH~7.4) was then added into the solution 
containing the pre-activated lactobionic acid mixture. Following that, the reaction was 
was left at room temperature overnight. The reaction mixture was then dialysed 
overnight against running DI water using cellulose ester dialysis membrane (MWCO 
500) to remove the salts and unreacted lactobionic acids, sulfo-NHS, and EDC. The 
Product, Gal-GE12, was purified with Agilent 1200 semi-preparative HPLC (Agilent, 
Santa Clara, U.S.A, with a gradient slowly ramping from 5% ACN to 25% ACN for 
the first 15 minutes, followed by quick ramping from 25% ACN to 100% for the next 5 
minutes. The synthetic peptides were characterized matrix-assisted laser 
desorption/ionization time-of-flight mass spectroscopy (MALDI-TOF MS, Model 
Autoflex II, Bruker Daltonics Inc., U.S.A.), where a-cyano-4-hydroxycinnamic acid 
was used as matrix. 
 
6.2.2.3. Ligand coating of cationic micellar nanoparticles 
Firstly, peptide/DNA complex was formed at intended N/P ratios with FA32 
nanoparticles according to the previously described method [152, 157]. After 
stabilization of the peptide/DNA complex, coating was performed by adding GalGE12 
ligand solution at different concentration to achieve different coating ratios (Figure 
6.1). The coating ratio was defined based on molar ratio of the peptide contained in the 
complex solution at any particular N/P ratios to that of the Gal-GE12 ligand molecules. 
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The volume ratio between ligand solution (L) and peptide/DNA complex solution (C) 
is kept constant at L:C = 1:4, at every N/P ratios and ligand concentrations. Upon 
mixing the the ligand and complex solutions, the mixture was let to equilibrate for 20 
minutes for the coating.  
 
6.2.2.4. Particle size and zeta potential measurement 
Effect of the ligand coating composition on the size and zeta potential of the 
resulting complex was measured by dynamic light scattering technique. The particle 
size was measured by dynamic light scattering instrument (Brookhaven Instrument 
Corp., Holtsville, NY, U.S.A.) and the zeta potential was measured using Zetasizer 
(Malvern Instrument Ltd., Worchestershire, UK), according to the method described in 
Section 3.2.2.7. 
 
6.2.2.5. DNA retardation assay 
Since both DNA and ligand coating share the same driving force for the 
attachment to the cationic micelle nanoparticles, a concern on whether DNA repulsion 
occur upon coating of the peptide/DNA complex with GalGE12 ligand or not might 
arise. In order to verify this, gel retardation assay was performed for complexes formed 
at N/P 5, 18, and 20 with several ligand coating compositions (0%, 10%, 20%, 40%, 
80% mole ratios). Post-equilibration, the ligand-coated complexes were 
electrophoresed on 1% agarose gel (stained with 4 μL of 0.5 μg/mL ethidium bromide 
per 50 mL of agarose solution) in 0.5×TBE buffer at 80 mV for 60 minutes. The gel 
was then analyzed on a UV illuminator (Chemi Genius, Evolve, Singapore) to show 
the position of the complexed DNA band relative to that of the naked DNA. 
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6.2.2.6. Cell culture 
HepG2 cell lines were cultured and grown according to the conditions 
described in Section 3.2.2.8.  
 
6.2.2.7. In vitro cytotoxicity and transfection 
Effect of ligand coating of the nanoparticles on its cytotoxicity was studied by 
measuring the cell viability of HepG2 cells after being treated with ligand-coated 
peptide/DNA complex formed at N/P 5, 18, and 20, coated with various coating ratios 
(0%, 10%, 20%, 40%, 80% mole ratios). Briefly, cells were incubated with the sample-
containing growth medium (20 mL of ligand-coated complex solution in 200 mL of 
fresh growth medium per well). After 4 hours of incubation, the cells were washed 
once with PBS buffer, and incubated with the fresh medium for further 68 hours. At 
the end of the incubation period, the cell viability were analyzed according to the 
protocol described in Section 3.2.2.9. 
Similarly, in order to study if the ligand-coating has any effect on the transgene 
expression efficiency, complexes at various N/P ratios (18 and 25) and coating 
compositions (0%, 10%, 20%, 40%, and 80%) were used for in vitro transfection 
experiment with luciferase-encoding plasmid. Briefly, HepG2 cell lines were seeded 
onto 24-well plates at a density of 8×104 cells/well respectively, and cultivated in 0.5 
mL of the respective growth medium. After 24 hours, the culture medium was replaced 
with fresh growth medium (supplemented with 10% FBS), and complex solution (50 
mL) containing 2.5 µg DNA was added to each well. After 4 hours of incubation, the 
culture media were replaced with the fresh ones. The culture media were removed after 
68 hours, and the cells were washed once with 0.5 mL of PBS and lysed with reporter 
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lysis buffer (0.2 mL) before being assayed according to the method described in 
Section 3.2.2.10 earlier.  
 
6.2.2.8. Targeted simultaneous delivery of p53 and doxorubicin 
Co-delivery of p53 (a therapeutic gene) and DOX was used to test the synergy 
in the anti-tumor activities between both therapeutics in HepG2 cells. The complexes 
were formed at various N/P ratios (5, 18, 20) and at a fixed DOX content of 0.025 
mg/L according to the previously described protocols. Coating of peptide/DNA 
complex (containing 2.5 mg of p53 DNA and 0.025mg/L DOX) were then performed 
at various coating composition (0%, 5%, 10%, 20%) to study the effect of the 
electrostatic ligand coating on the cytotoxic effect. The coating compositions for this 
study were varied at lower percentage range based on the analysis of the results on the 
effect of coating composition on the luciferase transgene expression. Briefly, HepG2 
cells seeded onto 96-well plates at 8,000 cells/well seeding density were treated with 
the complexes for 4 hours, followed by further incubation for 68 hours with fresh 
growth medium. Cell viability after the transfection with DOX-loaded FA32 
micelle/p53-encoding plasmid was analyzed with MTT assay at the end of 72 hours.  
 
6.3. Results and Discussions 
6.3.1. Peptide synthesis and galactosylation 
Table 6.1 summarizes the comparison between the theoretical and measured the 
molecular weight of the peptide synthesized in this study. Based on the 
characterization performed via MALDI TOF, the measured molecular weights of the 
peptides were found to be reasonably close to the theoretical ones, suggesting that the 
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synthesis and conjugation procedures were successful. The mass spectra measured via 
MALDI TOF are provided in Figure 6.2. 
 
Table 6.1 Molecular weight of peptide design 




GE12 GGGEEEEEEEEG-OH 1279.2 1282.6 






















6.3.2. Particle size and Zeta potential measurements 
Effect of ligand coating on particle size and zeta potentials were measured via 
dynamic light scattering technique. Figure 6.3 show various particle sizes at different 
ligand coating percentage for peptide/DNA complexes formed at low, medium, and 
high N/P ratio of 5, 18, and 20. As shown in the figure, the hydrodynamic sizes of the 
particles resulting from the complex coated with ligand are increasing slightly with 
higher coating ratio. On the other hand, the zeta potentials measurements show weak 
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since by performing electrostatic coating of negatively-charged ligand onto the 
cationic micelles complex, neutralization of excess positive charge would occur, and at 
the same time, deposition of the ligand molecules on the surface might lead to the 
increase of particle sizes. Moreover, taking into consideration that the ligand molecule 
contains only 12 amino acids and lactose moiety, the length added onto the coated 











Figure 6.3 Particle size (bar) and Zeta potentials (line) of galactose-coated peptide/DNA complex 
formed at N/P 5 ( , NP 5 Zeta), 18 ( , NP 18 Zeta), 20 ( , NP 25 Zeta). 
 
 
6.3.3. Effect of ligand adsorption on DNA binding 
Providing targeting ligand moiety via electrostatic adsorption offers a great 
advantage, particularly for carriers in the form of cationic micelles, whereby the DNA 
load is to be condensed on the surface of the vehicle (Figure 6.1). Should the targeting 
ligand for this type of carrier is chemically conjugated on the surface of the micelles 
prior to complexation with DNA, masking of the ligand molecule by the adsorbed 
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DNA might intuitively occur. However, since both DNA complexation and ligand 
adsorption shared similar driving force, it might be important to study if the ligand 
coating would competitively bind, or even to the extent of repelling the adsorbed DNA 
from the cationic micelle complex. This study is designed to revisit this possibility. As 
reported previously, FA32 peptide could condense DNA onto the micellar surface at 
N/P ratio 3 and above [157]. In this study, complexes were formed at N/P ratios 5, 18, 
and 20, at which DNA molecules should be completely bound to the micellar 
nanoparticles via electrostatic interactions. By subjecting these complexes to a varied 
ligand coating ratios, the effect of the presence of negatively-charged ligand on the 
bound peptide micelles could be shown. Figure 6.4 shows the DNA retardation profile 
for these complexes when subjected to different loading of negatively-charge ligand. It 
could be inferred from this figure that increasing the coating ratio up to 80% of the 
FA32 peptide content did not repel the DNA from the micellar surface, even at the low 






Figure 6.4 DNA retardation assay: DNA controls (lane 1 and 18); DNA/ligand mixture as negative 
control (lane 2); peptide/DNA complex formed at N/P 5 with ligand-coating at ratio of 0%, 10%, 20%, 
40%, and 80% (lane 3-7); peptide/DNA complex formed at N/P 18 with ligand-coating at ratio of 0%, 
10%, 20%, 40%, and 80% (lane 8-12); peptide/DNA complex formed at N/P 20 with ligand-coating at 
ratio of 0%, 10%, 20%, 40%, and 80% (lane 13-17). 
 
6.3.4. Effect of ligand adsorption on the cytotoxicity of DNA/peptide complex 
Cytotoxic effect of biomaterials is dependent on various factors; and it is 
generally accepted that several factors like the building blocks and/or degradation 
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products of the materials [192], or overall charge of the materials under physiological 
pH and ionic strength [193] contributes to its cytotoxicity. This study focus on the 
variation of the ligand coating ratio in order to evaluate the cytotoxic effect of the 
peptide/DNA complex as a result of ligand attachment. Figure 6.5 shows the cell 
viability of HepG2 cells after being treated with peptide/DNA complex coated with 
various composition of GalGE12 targeting ligand. N/P ratio chosen for this study are 
N/P 5, 18, and 20, to evaluate on the same effect at low (non-transfecting) N/P ratios, 
as well as at high (optimal and transfecting) N/P ratios, as characterized before in 
another study [157]. As shown in the figure, statistically, there is no significant 
difference between the cytotoxicity of the peptides/DNA complex after being coated 
up to 80% coating ratio. This experiment suggests that addition the small 
glycopeptides (GalGE12) sequence to the complex did not alter the cytotoxicity 
profile, plausibly because the glycopeptides were made of natural building blocks and 










Figure 6.5 Effect of Electrostatically-driven ligand coating on cytotoxicity of peptide/DNA complex 
formed at N/P 5 ( ), 18 ( ), and 20 ( ). 
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6.3.5. Effect of ligand adsorption on transgene expression 
In order to evaluate the effect of ligand coating on the transgene expression, 
peptide/DNA complex was also coated at various coating ratios at high (transfecting) 
N/P ratios, as characterized before in another study [157]. Figure 6.6 shows that 
addition of GalGE12 ligand via electrostatic coating initially increases the luciferase 
transgene expression in HepG2 cells, bearing the ASGPR, presumably due to the 
increased in cellular uptake of the complex. This observation is in aggrement to the 
study reported previously that ligand attachment could increase the transgene 
expression on the cell bearing receptor to recognize the electrostatically-coated ligand 
[128]. However, an optimum point for the coating ratio was observed in this study. The 













Figure 6.6 Effect of Electrostatically-driven ligand coating of peptide/DNA complex formed at N/P 18 
( ) and 25 ( ) on transgene expression efficiency. 
 
6.3.6. Targeted simultaneous delivery of p53 and doxorubicin 
The benefit of designing a cationic micelle system as therapeutic carrier was 
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opposing properties, such as hydrophobic drugs and hydrophilic negatively charged 
nucleic acids or protein drugs. We have reported the application of such system for 
simultaneous delivery of these types of drugs in achieving synergies for anti 
proliferative effect towards HepG2 model cancer cell line [157]. However, since the 
driving force for the nucleic acid/protein drug incorporation was based on electrostatic 
interaction with the surface of the cationic micelles, attachment of targeting ligand or 
anti-stealth moiety, such as PEG, onto the cationic micelle become less straight 
forward. The presence of such molecules might easily hinder the interaction between 
the carrier and the load, and at the same time might also mask off the ligand from 
receptor recognition. For example, we have previously reported that PEGylation of 
cationic micelles self-assembled from an amphiphilic polymer resulted in less effective 
gene binding [118]. The advantage of implementing electrostatic ligand interaction 
will be demonstrated here for multimodal anticancer treatment using DOX and p53-
encoding plasmid.   
Figure 6.7 represents the cytotoxic effect of simultaneous delivery of DOX and 
p53-encoding plasmid using FA32 peptide micellar nanoparticles as the carrier. It was 
shown in the figure that when the peptide/DNA complex (containing 0.025 mg/mL 
DOX) was formed at N/P 5 (weakly transfecting ratio), or N/P 18 and 20 (efficiently 
transfecting ratio), there is an increasing trend of cytotoxicity as the coating ratio is 
increased from 0% to 20%. It is therefore apparent that ligand coating via electrostatic 
adsorption might offer particularly useful way of incorporating targeting ligand onto 
cationic micellar delivery system for multi-modal drug and gene delivery system. In 
addition, similar strategy could also be applied for PEGylation of cationic micelle 
delivery systems, which would enhance systemic circulations of such system 
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Figure 6.7 Effect of electrostatically-driven ligand coating on anti-proliferative effect of p53 ( ), or 
combined cytotoxic effect of p53 and DOX ( ).   
 
6.4. Conclusions 
In conclusion, a short peptide containing block of negatively-charged peptide 
bearing Galactose moiety at the N-terminal has been designed and synthesized. 
Adsorption of this ligand onto a cationic micelles complexing DNA molecule on its 
surface was performed and characterized via dynamic light scattering and zeta 
portential measurement. It was found that the particle size of peptide/DNA complex 
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was increased upon ligand coating, while the zeta potential gets reduced. Gel 
retardataion assay was performed to show that there was no repulsion of DNA cargo 
from the complex resulting from the ligand coating, despite both DNA and ligand 
adsorption sharing the same driving force. In vitro effect of the ligand coating on 
cellular cytotoxicity and transgene expression of FA32 peptide/DNA complex were 
also revisited. It was found out that the ligand coating did not exhibit significant 
changes in the cytotoxicity profile of the peptide/DNA complex, while increasing the 
luciferase transgene expression (within the same order of magnitude) at coating ratio 
of less than 20%. Finally, targeted simultaneous delivery of p53-encoding plasmid 
with DOX was demonstrated to show the effect of the targeting ligand in increasing 
synergistic cytotoxic profile of the two therapeutic molecules. This study may provide 
a platform for incorporation of targeting ligand and/or PEGylation of cationic micelle 
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CONCLUSIONS AND RECOMMENDATIONS 
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Cancer research in the recent years has witnessed tremendous potential 
applications of nanotechnology products, in particular in disease diagnostics and 
therapy technologies. This thesis was designed to study the application of 
nanotechnology in cancer therapy, particularly in developing new class of 
biocompatible materials that enables the formation of nano-carriers for anticancer drug 
and/or gene delivery.  
Biomaterials designed in this study belong to the class of cationic and 
amphiphilic peptides. In comparison with the currently available/researched 
biodegradable polymers, peptides were intuitively much more compatible for the 
intracellular environment, since it is made of natural amino acids. In addition, the 
designed peptides in this study were entirely synthetic, based on the rationale for 
providing certain intracellular delivery mechanisms, without any derivative sequences 
from any living microorganisms being present. Moreover, the productions of the 
peptides were also carried out through a chemical synthesis method, which would 
minimize the contamination from microorganisms; hence minimizing the possibility of 
immunogenic response should the results in this study be translated into in vivo 
studies. 
The works in this thesis was first started by designing the sequence of the 
peptide amphiphile that would self-assemble into micelles in a physiological 
environment, and at the same time could provide desired properties for intracellular 
gene delivery. It was shown that short peptide consisting three blocks of amino acids 
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comprising 12 alanine, 5 histidine, and 10 or 15 lysine residues (AK27 or AK32) could 
self-assemble into micellar nanoparticles and induce efficient transgene expressions in 
various mammalian cell lines with minimal cytotoxicity. Following that, a more stable 
and “compact” peptide nanostructure assembly was achieved by systematically 
tailoring the hydrophobic content of the peptide amphiphile. A new generation of 
peptide amphiphile containing 6 repeats of alanine and phenylalanine forming the 
hydrophobic block (FA32) was found out to be capable for simultaneous delivery of 
drug and gene.  
Having obtained an amphiphilic peptide sequence with more stable 
micellization behavior, application of the “optimized” peptide micellar assemblies 
(FA32) in co-delivery of anticancer drug (doxorubicin) and gene (p53-expressing 
DNA) was performed, and it was shown that synergistic effects between these 
therapeutic agents could be achieved in a liver cancer model (HepG2) cell line. Better 
killing efficacy of doxorubicin towards the model cell line was achieved at the end-
point cytotoxicity level, through the elevation of p53 tumor suppressor proteins, as 
indirectly evidenced by the increase in intracellular mRNA expression level. Finally, 
using the same model cell line that has been reported to over-express ASGPR receptor, 
a targeted co-delivery system using electrically-driven ligand attachment containing 
galactose moiety was proposed. It has been demonstrated that electrostatic interaction 
between ligand and carrier could be used in achieving targeted simultaneous delivery 
of p53 and doxorubicin using cationic micelles. The author therefore believes that the 
studies presented in this thesis would contribute in its own unique ways to the current 
richness of the field of nanotechnology for cancer therapy. 
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7.2. Recommendations for Future Works 
Despite the research progress and improved understanding on cancer hallmarks 
and behaviors, cancer is still undoubtedly regarded as one of the most potent “silent” 
killer of mankind. Nanotechnologies have become increasingly important in offering 
ways and alternative cures for cancers; however, the impact of this progress is still yet 
to be realized in clinical applications. The research activities in this field, including 
that presented in this thesis, have definitely contributed to enrich the knowledge in 
cancer nanotechnology. Nevertheless, the author would still like to make some 
recommendations for future works to provide a better ground for justification if the 
class of biomaterials being researched in this thesis would be suitable to contribute in 
real clinical settings for the benefit of human life. As it might have been known, 
excellent in vitro results might not always translate to the same direction in vivo. 
Although the works presented in this thesis has shown some promising in vitro data, it 
is however, still insufficient to move this technology forward for clinical use at this 
stage. As such, in vivo works need to be carried out for further justifications. 
Realizing the wide spectrum of in vivo works that could be included, the author 
would recommend devising this recommendation into several stages. The first and key 
determining stage will be investigating the immunogenicity of the synthetically 
designed peptides. This stage will serve as the “make or break” call for further 
translation of this technology into examining its functionalities in the presence of real 
in vivo barriers. Should the synthetic peptide be confirmed to be non-immunogenic – 
via both specific antibody-antigen recognitions and non-specific Interferons (IFN’s) 
pathways, and thus completely safe for in vivo applications, a second stage of in vivo 
studies could also be devised in an animal cancer model. At this stage, one could aim 
to study the biodistributions and targeting capabilities of the carrier to evaluate the 
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efficacy of electrostatic coating of active targeting ligand to selectively target tumor 
sites bearing its complementary binding receptors. Following that, reduction in tumor 
volume could also be measured against various control treatment groups to evaluate 
the efficacy of the proposed co-delivery system in this thesis for cancer treatment in 
vivo. 
Although the recommendations for future works suggested here might sound as 
exhaustive as the completed works to date, they were not made to discount the 
contribution of the study presented in this thesis to the current richness of the field of 
cancer therapy with nanotechnology products. It was mainly to express the author’s 
humble realization on the different barriers presenting in vitro and in vivo studies, 
hence the need for further in vivo studies to justify the potential applicability of the 
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